

# **FPD17**

(In connection with Application No. 10/762,566)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number  
WO 02/062322 A2

(51) International Patent Classification<sup>7</sup>: A61K 31/00

(21) International Application Number: PCT/BE02/00013

(22) International Filing Date: 4 February 2002 (04.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2001/0085 5 February 2001 (05.02.2001) BE

09/945,391 31 August 2001 (31.08.2001) US

PCT/BE01/00222

21 December 2001 (21.12.2001) BE

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(71) Applicant and

(72) Inventor: MESSADEK, Jallal [BE/BE]; Place des Béguinages 2, B-4000 Liège (BE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GLYCINE BETAINE AND ITS USE

(57) Abstract: A pharmaceutical combination comprising a therapeutic effective amount of a therapeutically active agent with at least one haemorrhagic side effect, and a therapeutic effective amount of a compound of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with  $n$  an integer from 1 to 5 for preventing or reducing said haemorrhagic side effect.



WO 02/062322 A2

## GLYCINE BETAINE AND ITS USE

### FIELD OF THE INVENTION

- 5 This invention relates to the use of glycine betaine to eliminate physiopathological vascular attacks. The invention relates to the curative and preventive activity of glycine betaine in the pathogenesis of thrombo-embolic and haemostatic diseases of arterial or venous origin.
- 10 Glycine betaine exhibits preventive activity while preventing the formation of thrombi and exhibits a curative activity which prevents the proliferation of thrombi while destroying them. The significance of the present invention is based on the fact that the use of glycine betaine does not result in any risk of haemorrhage or allergy in opposition to the molecules and treatments currently used.

15

### PRIOR ART

- Vascular thromboses are a response of the organism which is facing attack on a vessel wall and on the content of cells and plasma thereof. Thrombosis is a localised
- 20 activation of coagulation with the formation of a thrombus.

The interest to which this pathology has been subjected in recent years has enabled several causative factors to be identified:

- the vessel, the vascular wall and the endothelial cells,
- 25 - the role of elements which occur in blood
- the coagulation and fibrinolysis systems, and inhibitors thereof.

- Several types of thromboses exist which can occur in arteries, in veins, in the micro-circulation of the organs, in the cavities of the heart and at artificial surfaces in
- 30 contact with blood. Vascular thromboses are a response to the attack on the vessel wall and on its content of cells and plasma. A thrombosis is an organised mass of

blood elements (platelets, red corpuscles and white corpuscles), of fibrin and of other plasma proteins, which are deposited at the surface or which obstruct the free passage of the vascular system.

- 5     The mechanisms of thrombosis resemble those of haemostatis, but are pathological due to their abnormal intravascular location.

Thromboses and embolisms are the main reasons for clinical complications associated with cardiovascular diseases and atherosclerosis.

10

According to Virchow, at least three types of thrombogenic factors determine the location, the extent and the regression of a thrombosis:

- haemodynamic and rheological factors;
- 15    -     endothelial lesion;
- activation of the constituents of blood, particularly of platelets, and of coagulation which results in the formation of thrombin.

20     Thrombo-embolic disease of arterial or venous origin remains one of the main reasons of death in developed countries.

Arterial thrombosis is often due to a rupture of the atherosclerotic plaque, whereas venous thrombosis results from a deficit of a coagulation inhibitor (AT III) or from a deficit of a fibrinolysis activator (S protein and/or C protein) or more frequently from  
25     stasis. In fact, both of these result from an interaction between blood and the vascular wall, from the formation of a venous thrombosis and/or from a haemostatic anomaly. Arterial thrombosis is more often secondary to a parietal anomaly and mainly involves blood platelets. It contributes to a wide variety of clinical pictures depending on the arterial layers involved in the interruption of vascularisation.  
30     Thrombosis is mainly capable of affecting the cardiac arteries (coronary), and the arteries of the lower, cerebral or digestive organs. Thus arterial disease favours the

formation of the thrombus itself which is responsible for the majority of terminal vascular occlusions. Moreover, participation of haemostatic disorders and of the thrombus formed at other vascular lesions is evident: aggravation of the lesions of the vascular wall, ischemia and problems in the micro-circulation.

5

Three therapeutic strategies can be distinguished for the prevention of accidents associated with thromboses:

Anticoagulants. These constitute the major element in the treatment of a patient exhibiting a thrombo-embolic disorder. Heparin and derivatives thereof are currently  
10 used. However, the use of heparins can give rise to two major complications, namely haemorrhage or thrombopenia.

K antivitamins (KAV). Prescribed for long-term treatment, these cannot be used in  
15 an emergency and cannot be prescribed simultaneously with other anti-aggregants, since they potentiate the haemorrhagic effect thereof.

Platelet antiaggregants. Prescribed to prevent arterial thrombosis associated with atherosclerosis. The main inhibitors of platelet functioning which are currently  
20 prescribed are: aspirin, ticlopidine, dipyridamole, and certain non-steroid anti-inflammatory agents such as flurbiprofen and prostacyclin. These treatments are really effective, but have undesirable effects on patients subject to allergies or haemorrhage.

25 Despite their efficacy, all these treatments necessitate special precautions in use, such as the administration of antidotes, overdose problems and unwanted side effects. These treatments make it necessary to monitor patients, due in particular to haemorrhage-related problems which can arise during or after medication, as well as possible incompatibility with other drugs. It was therefore of interest to identify a  
30 molecule having a high antithrombotic potential without undesirable effects. Most

surprisingly, glycine betaine has been identified as possessing a high therapeutic potential for in the treatment of thromboses.

Glycine betaine, or betaine of formula  $(\text{CH}_3)_3\text{N}^+ - (\text{CH}_2) - \text{COO}^-$ , is a molecule known for its osmo-protective properties and for its cosmetic and pharmaceutical uses. Various pharmaceutical uses of betaine are known, particularly the use of betaine for the treatment of homocystinuria, which causes cardiovascular problems (L. & B. Wilken, J. Inher. Metab. Dis. 1997). Thus patients suffering from homocystinuria, which is a genetic anomaly, exhibit premature atherosclerotic and thrombo-embolic disorders (S.H. Mudd et al., The metabolism and molecular bases of inherited disease, 1995), and of cardiovascular diseases (McCully, Atherosclerosis Rev. 11, 1983). Homocystinuria is a hereditary deficiency, the homozygotic form of which is rare. It is estimated that the prevalence of this homozygotic form corresponds to 1 in 200 in the general population.

15

Homocystinuria is due to elevated levels of homocysteine in the plasma of the affected patient. The administration of betaine enables the concentration of homocysteine in the blood to be reduced.

20 Publication WO 951 157 50 proposes the use of ingredients comprising betaine in order to prevent vascular disorders in homocystinuric patients.

Publication WO 98 /19690 also relates to patients suffering from an elevated homocysteine level in their blood. The use of betaine amongst other ingredients is intended to reduce the level of homocysteine in the blood, it having been established that homocysteine is a positive factor of risk in the occurrence of cardiovascular diseases, as well as in Alzheimer's disease.

Publication EP 0 347 864 describes the use of betaine together with other ingredients in order to combat the increase in sulfhydryl groups, which are due to cysteine and to

30

homocysteine, in human plasma, and thus to inhibit the formation of atherosclerotic plaques.

5 This anti-atherosclerotic effect is known and is extensively documented. These publications relate to the effect of betaine on the metabolism of lipids (Zapadnyuk et al. Biol. Med. 1987), and on that of cholesterol (Panteleimonova et al., Farmakol. Toksikol, Moscow 1983).

10 Publication WO 97 38685 describes the use of betaine and taurine for the treatment of complications resulting from ischemia in some organs. Ischemia is a localised stoppage of the bloodstream and only represents one of the pathologies due to thrombosis.

15 Publication EP 0 781 554 comprises examples which describe experiments on enucleated hearts, i.e. on hearts which have been extracted and isolated from the vascular system. The use of betaine for its known osmoprotective and antiradical properties enables the inventors to claim a protective action thereof on the cardiac muscle.

20 Other forms of betaine have been proposed (WO 97 / 06795), but have not hitherto equaled the potency and performance of glycine betaine.

None of these publications discloses the potency of glycine betaine with respect to venous and/or arterial thrombosis, nor its anti-aggregant and anticoagulant potency.

25

WO 0051596 of applicant, the scope of which is incorporated by reference, discloses the use of betaine for the treatment of thrombosis not induced by homocystinuria. In examples, said application discloses the combination of glycine betaine with a contrast agent.

30

Said document does not disclose the pharmaceutical combination of a therapeutic agent (an agent for treating a trouble or for preventing a trouble for a patient, especially a mammal) with glycine betaine, nor the advantages of such a combination. Possible advantages of such a combination is the reduction of haemorrhagic side effects and/or potentializing the therapeutic effect of said active agent. It has to be noted that due to reduction of haemorrhagic side effect, it is possible to treat more efficiently the pathology, as the dosage of the therapeutic agent can be increased if required. Furthermore, for drugs, such as antithrombotic drugs, it was observed that the antithrombotic effect of the drug was even potentialized.

10

The invention relates thus among others to :

- A pharmaceutical combination comprising a therapeutic effective amount of a therapeutically active agent with at least one haemorrhagic side effect, and a therapeutic effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof for preventing or reducing said haemorrhagic side effect and/or for potentializing the therapeutic effect of said active agent;
- Process of treatment of a patient in need for treating or preventing a trouble by administering to said patient an effective amount of a therapeutic active agent with at least possible one side haemorrhagic side effect, in which an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof for preventing or reducing said side effect and/or for potentializing the therapeutic effect of said therapeutically active agent;
- A controlled release pharmaceutical system suitable for delivering in a controlled manner to the bloodstream of a mammalian a betaine or an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof, esters



thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof ;

- A controlled release pharmaceutical system for releasing an effective therapeutically amount of at least a compound selected from the group consisting of betaines or an effective amount of a compound of formula  
 5  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof, for treating or preventing blood flow disturbances.

10

#### BRIEF DESCRIPTION OF THE INVENTION

Glycine betaine, as well as betaine compounds of the general formula

$(\text{CH}_3)_3\text{N}^+ - (\text{CH}_2)_n - \text{COO}^-$ , with n varying from 1 to 5 (preferably equal to 1) in the

- 15 context of the present invention can be used for various clinical applications, such as: coronary thromboses and venous thromboses

- thromboses and re occlusion of the vascular system following a thrombolysis or an angioplasty
- infarct, angina pectoris, aneurysm, pulmonary embolism, phlebitis
- 20 - cerebral embolism
- post-traumatic shock, whether or not of surgical origin
- prevention of accidents of microcirculation in the following cases: haemophilia, chemotherapy, ageing, oral contraception using oestrogens, obesity, tobacco addiction, prosthesis, diabetes.
- 25 prevention of the risks associated with the administration of contrasting ionic and non ionic products.

The extracorporeal circulation and the haemodialysis procedures. The blood in contact with artificial surfaces of patients subject to an extracorporeal circulation has a risk of formation of platelet nails, of thrombi and embolism. These risks can be prevented  
 30 by administering the compound(s) of the invention before and/or during and/or after these procedures.

Inflammation phenomena. When binding it with integrine of Mac-1 receptor of the leukocytes and by reducing the expression of mitogenes and pro inflammation cytokines. When acting on the Mac-1 receptor, the compounds of the invention reduce the adhesive and migration properties of the leukocytes reducing thereby the tissue aggression.

Haemostatic glues. By allowing, in function of pathologies, the gel time of the glues, while reducing secondary effects due to their uses.

Stings and bites of venomous animals. Experimental data show that the injection of compounds of the invention to rats to which a venom lethal dose is injected, delays the death thereof. The compounds of the invention are therefore suitable for entering into antidote composition for venom, possibly in combination with other antivenomous compound(s).

Prevention of blood circulation problems due to contact with artificial surfaces, such as biomaterial elements, prosthesis, etc. (cardiac valves, balloons, catheters, hip prosthesis, stents etc.). When using these elements with betaine, the secondary effects are reduced. **Moreover coating these exogenous materials with betaine avoid problems as reocclusion, rethrombosis and restinosis.**

Metastasis Prevention of cancerous cells. This anti tumoral activity is bound to the fact that cancerous cells released from tumours are transported by the micro thrombi inside the vascular system. These cancerous cells are undetectable by the immune system able to destroy them. Moreover, their incorporation in the micro thrombi facilitates their binding to the vascular system or in the organs, and creates then new cancerous colonies. As the formation of thrombi is function to the adhesion of fibrinogen to glycoprotein IIb IIIa site on the activated platelets, an antagonist of fibrinogen adhesion has an antimetastasis activity by permitting the immune system to detect the cancerous cells during their migration, and by removing the vehicle (thrombus) enabling their transport and their binding. The compounds of the invention can be administered alone or with other anticancerous compounds (simultaneous administration or not) so as to improve their efficiency and the process of angiogenesis during malignant melanomas.

Process for detecting and localizing thrombi by binding compounds of the invention to a portion detectable in vivo and/or in vitro.

Process for avoiding thrombo-embolic problems correlated to air trips. In view of its very low toxicity and its blood fluidifying characteristics, the betaine can be  
5 administered in the form of patch, sweets, confectioneries, cookies, drinks, meals, candies, etc. so as to prevent thromboembolic events for airplane /flight passengers.

Sweetener for diabetes, the betaine being or not associated with another sweetener. As Betaine is a residue of sugar production, betaine has some sweetening properties which can be used for the preparation of sweetener with anti aggregation properties.  
10 Said sweetener, while avoiding circulation problems bound to diabetes, could improve the efficiency of insulins. It has been demonstrated that the activation of vitronectin receptors facilitates the cell migration and provides the necessary signals for the regulation and proliferation of cells, and potentialises the insulin effect (Ruoslahti, Kidney Int., 1997, 51, 1413-1417)

15 Process for individualizing cells in culture in vitro

As anti bacterial and anti infectious

Use of a compound of the invention ( compound of the general formula  $(\text{CH}_3)_3\text{N}^+ - (\text{CH}_2)_n - \text{COO}^-$ , with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts, for the  
20 preparation of a pharmaceutical composition for the treatment or for the prevention of troubles bound to one or more glycoproteins, especially to the receptor of one or more glycoproteins, preferably to the receptor of glycoprotein IIb IIIa.

Use of a compound of the invention ( compound of the general formula  $(\text{CH}_3)_3\text{N}^+ - (\text{CH}_2)_n - \text{COO}^-$ , with n an integer from 1 to 5, preferably equal to 1, or a mixture of  
25 such compounds or one or more pharmaceutically acceptable salts for potentializing the therapeutical effect of a pharmaceutical active agent.

Platelet aggregation is an essential event in the formation of blood clot and thrombus. In normal conditions, following a vascular lesion, blood clots prevent blood losses by  
30 closing the opening. However, in some pathological instances, the formation of a

blood clot can reduce partly or completely the blood circulation, with the consequence of a cellular necrosis.

For example, the platelet aggregation and thus the thrombosis at the level of the  
5 artherosclerosis plaques is an important factor for the genesis of conditions such as  
angina pectoris, myocardus infarct, vessel occlusion following a thrombolysis or an  
angioplasty. Patients suffering a heart attack are treated with thrombolytic agents  
such as plasmin activators and the streptokinases which dissolve the fibrin from the  
clots. A major complication of this therapy is the reocclusion of vessels due to  
10 platelet aggregation, which can lead to irreversible damages to the heart, the brain or  
other organs.

Thrombosis starts with the adhesion of platelets at the vascular lesion sites. The  
platelet adhesion is initiated by the receptor located at the surface of the platelets  
15 which bind to proteins of the extracellular cellular matrix of the exposed  
endothelium, such as fibrinogen, fibronectin, Von Willebrand factor, as well as other  
adhesive proteins such as vibronectin, collagen and laminin. Therefor, the activation  
of platelets is a reply to agonists such as epinephrine, ADP, collagen, the arachidonic  
acid or the thrombin. This activation leads to the activation of the glycoprotein Ib  
20 receptor (GP Ib) and/or of the glycoprotein IIb IIIa receptor (GP IIb IIIa) at the  
surface of the platelets. This receptor(s) (GP Ib and/or GP IIb IIIa) is/are then  
available for its/their binding to fibrinogen and the platelet aggregation. The adhesion  
of the receptor (GP IIb IIIa) to other adhesive proteins such as the Von Willebrand  
factor also leads the attachment of platelets between them and their aggregation. The  
25 adhesion of molecules such as fibrinogen or the Von Willebrand factor to the  
receptor (GP IIb IIIa) leading the platelet aggregation is an essential step in the  
formation of the thrombus. The receptor (GP IIb IIIa ) is thus a privileged target for  
the new therapy treating thrombosis and thromboembolic pathologies.  
Furthermore, the use of antagonists of the glycoprotein IIb IIIa receptor inhibits the  
30 platelet aggregation, while respecting the other hemostasis mechanisms, is highly  
desirable in the new therapies bound to thrombosis. Several molecules having this

antagonist property are marketed with usage restrictions due to immunoreactivity problems, toxicity, allergy or hypersensitivity reactions for some patients. A subject matter of the present invention is to propose a molecule, especially a well-known and used molecule of vegetal origin, having this antagonist activity for the glycoprotein IIB IIIa receptor, while not having toxic characteristics.

It is also known that the activation of the vitronectin receptor improves the cell migration and provides regulating signals of the cell proliferation and cell differentiation, and activates the effects of insulin (Ruoslahti, Kidney Int., 1997, 51, 1413-1417). The regulation of the vitronectin receptor is associated with pathological conditions, such as vascular restinosis (Clemetson and Clemetson, Cell.Mol. Life Sci., 1998,54,502-513), bone excess resorbtion (Rodan and Rodan, J. Endocrinol., 1997, 154 Suppl, S47-56), and the angiogenesis process during the malignant melanomas (Cheresh, Cancer Metastasis Rev., 1991, 10,3-10).

Surprisingly, it has now been found that betaines of formula  $(\text{CH}_3)_3\text{N}^+ - (\text{CH}_2)_n - \text{COO}^-$ , with n an integer from 1 to 5, and their pharmaceutically acceptable salts, have an antagonist activity for one or more glycoprotein(s) receptors, such as the glycoprotein Ib receptor and the glycoprotein IIB IIIa receptor, by inhibiting the platelet aggregation induced by various agonists. This antagonist activity is not restricted to the glycoprotein site IIB IIIa but to all glycoprotein sites implicated in the cell adhesion of various origins, there between.

Platelets are activated by some agonists, whereby their forms, as well as their secretions of their granules can be modified, and whereby the aggregation thereof can be induced and the formation of clots and thrombi can be produced.

Several endogenous agonists, such as ADP (adenosine-5-diphosphate), serotonin, arachidonic acid, epinephrine, adrenaline, thrombin, collagen, ristocetine are known.

Recently a mechanism of action of these agonists has been identified, namely the activation of the glycoproteic site GP IIb IIIa which causes the adhesion of the circulating fibrinogen (Thromb. Res. 1993, 72, 231-245) and therefore the consolidation of platelets groups and the formation of clot. (Drug of the future, 1994,  
5 19 (2), 135-159)

The actually used platelet aggregation inhibitors are acting only on a single agonist. For example, aspirin is active against the arachidonic acid, ticlopidin is active against ADP, hirudin is active against thrombin. The betaines of the general formula of the  
10 invention disclosed here before are actives against various agonists, as well as on fibrinogen, fibronectin, Von Willebrand factor and other adhesive proteins such as vitronectin, collagen, laminin. This is a major improvement for their efficiency, while preserving the hemostasis mechanism so as to avoid haemorrhagic or bleeding events. Due to their activity by oral administration, said compounds are excellent  
15 candidates for pathologies with adhesion of cells between them.

In view of its very low toxicity and its efficiency, the best results have been obtained with glycine betaine (compound of the general formula with  $n = 1$ ).

None of the publications to which reference is made in the present specification teach  
20 the antagonist activity of the betaine with respect to glycoprotein IIb IIIa receptor, nor its activity with respect to adhesive proteins. This antagonist activity is not only limited to the site of glycoprotein IIb IIIa, but also to all the other glycoproteic sites acting in the adhesion of cells of various origins there between.

25 In the present specification, pharmaceutically acceptable salts are salts of betaine which can be administered, such as salts of betaine with hydrochloric acid, sulfuric acid, sulfonic acid, organic acids such as acetic acid, citric acid, tartaric acid, formic acid, etc., as well as the monohydrate radical.

30 Betaines, preferably glycine betaine, is advantageously administered orally, parenterally, sub cutaneously, by suppositories, tablets, capsules, syrup, etc.

Administered doses can vary from 0.001 g to 10 g per kg live body, for example from 0.005 g to 5 g, in particular from 0.01 g to 3 g per kg live body.

Examples of administration forms are : tablets, capsules, patches, injectable forms, releasing forms, sublingual administration form, powder (for example for inhalation therapy, buccal inhalation), syrup, solution (nebulization, for example for inhalation therapy, buccal inhalation). As preferred administration forms, subcutaneous injectable dosage form, patches (to be applied on the skin) and entero soluble oral dosage form, such as gastro insoluble tablets or capsules, etc. provided with an entero soluble coating or matrix or system.

As the pH of an aqueous glycine betaine solution is comprised between about 6 and about 7, an injectable solution (preferably for a subcutaneous injection) can be prepared by mixing solid glycine betaine with water (sterilized and possibly demineralized). The glycine betaine can be in the form of a powder (lyophilized powder) placed in a vial, water is then added to said vial for the preparation of the solution to be injected. If necessary, some acid (such as hydrochloric ) can be added to the solution or to the water to be mixed with the powder.

The injectable dosage form can be a pressurized dosage form, such as an air pressurized dosage form. Subcutaneous injectable forms of glycine betaine, such as intravenous injectable forms, are preferred. Glycine betaine injectable forms are for example aqueous solution containing 0.1 to 50% by weight glycine betaine, advantageously from 0.5 to 30%, preferably from 10 to 20%. The injectable form has a pH for example comprised between 5 and 8.5, advantageously from 6 to 7.5, preferably from 6 to 6.5. When the injectable form is prepared by mixing glycine betaine (as a solid form or as a powder form), the pH of the solution is about 6 – 6.5.

When the glycine betaine is administered by injection, the glycine betaine can be present in a solution of a flexible bag (baxter), for example a flexible bag (baxter) for

intravenous administration of a saline solution, or a physiological solution, or a blood transfusion baxter.

The invention relate thus also to a bag (flexible bag or baxter) for subcutaneous administration (preferably intravenous administration) containing a solution suitable for subcutaneous administration. As more specific example, the bag or baxter contains blood or a blood derivative or a blood portion and glycine betaine for subcutaneous administration.

Another subject matter of the invention is a pharmaceutical composition (such as a tablet) containing insulin and betaine, a pharmaceutical composition (such as a tablet) containing an antibiotic and betaine, a pharmaceutical composition (such as a tablet) containing an anti cancerous agent and betaine, a pharmaceutical composition (such as a tablet) containing aspirin and betaine, etc.

15

A subject matter of the invention is thus a pharmaceutical combination comprising an effective amount of betaine (preferably glycine betaine) and an effective amount of another active agent for the prevention or treatment of troubles.

Advantageously, the pharmaceutical combination comprises an effective amount of an active agent for the treatment and/or prevention of a trouble, said active agent having at least one side effect selected among the group consisting of haemorrhagic events, coagulation troubles, thromboses and associations thereof, and an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$ , with n an integer from 1 to 5, preferably equal to 1, for preventing at least 50%, advantageously at least 75%, preferably at least 90%, most preferably substantially completely said troubles and/or for reducing the seriousness of said side effect, advantageously of a factor of at least 50%, preferably of at least 75%, most preferably of at least 90%, especially substantially completely.

Betaine is preferably used as anti haemorrhagic agent in said combination.



Betaine is preferably used as an antidote to an haemorrhagic agent in said combination.

The pharmaceutical combination can be in the form of a kit, so as to prepare the combination before administration or during the administration.

- 5 Side effect is defined as being events observed more than 2% for the patients in treatment with the active agent. By combining said active agent with betaine, it is possible to reduce drastically said events, for example to less than 2%, as well as the importance or gravity of said events.

The active agent with possible side effect is advantageously selected among the  
10 group consisting of contrast agents, anti inflammatory agents, anti aggregation agents, anti coagulation agents, anti thrombotic agents, thrombolytic agents, Tpa agents, anti cholesterol agents, anti vitamin K and mixtures thereof. Specific examples of such agents are glycoaminoglycans, heparins (such unfractionated heparin, standard heparin, low molecular heparins, heparinoid, and mixtures thereof),  
15 heparin-like molecules (such as heparinoid, danaparoid, orgaran, fragmin, dalteparin, enoxaparine, lovenox, ardeparin, normiflo and mixtures thereof), thrombin inhibitor (such as argatroban, novastan, and mixtures thereof), aspirin, anti inflammatory agents (such as non steroid anti inflammatory agents), anti aggregation agents, anti coagulation agents, antiplatelet agents (such as dextrans, dipryridamole,  
20 sulfinpyrazone, ticlodipine, abciximab, tirofiban, mixtures thereof), anti thrombotic agents, thrombolytic agents (such as human recombinant activated protein, tissue plasminogen activator, urokinase, streptokinase, anistreplase/APSAC, and mixtures thereof), anti cholesterol agents, anti vitamin K, Tpa agents (tissue plasminogen activator), glycoaminoglycans, heparinoid agents, hirudins, anti vitamin K, warfarins,  
25 coumadin, coumarin, agents of the statin family, ticlopidine, statin agents, cerivastatine, simvastatin, lovastatin, agents of the statin family, cerivastatine (Baycol), simvastatin, lovastatin, etc.

The invention relates also to the use of a compound of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$   
30 with n an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof, esters thereof, precursors thereof, precursors thereof,

precursors thereof, and mixtures thereof, as active antidote agent for the preparation of an antidote composition, for example for combating haemorrhagic troubles, such as haemorrhagic troubles caused by one or more agents selected from the group consisting of :

- 5 contrast agents, anti inflammatory agents, anti aggregation agents, anti coagulation agents, anti thrombotic agents, thrombolytic agents, Tpa agents, anti cholesterol agents, anti vitamin K and mixtures thereof. Specific examples of such agents are glycoaminoglycans, heparins (such unfractionated heparin, standard heparin, low molecular heparin, heparinoid, and mixtures thereof), heparin-like molecules (such as
- 10 heparinoid, danaparoid, orgaran, fragmin, dalteparin, enoxaparine, lovenox, ardeparin, normiflo and mixtures thereof), thrombin inhibitor (such as argatroban, novastan, and mixtures thereof), aspirin, anti inflammatory agents (such as non steroid anti inflammatory agents), anti aggregation agents, anti coagulation agents, antiplatelet agents (such as dextrans, dipryridamole, sulfinpyrazone, ticlodipine,
- 15 abciximab, tirofiban, mixtures thereof), anti thrombotic agents, thrombolytic agents (such as human recombinant activated protein, tissue plasminogen activator, urokinase, streptokinase, anistreplase/APSAC, and mixtures thereof), anti cholesterol agents, anti vitamin K, Tpa agents (tissue plasminogen activator), glycoaminoglycans, heparinoid agents, hirudins, anti vitamin K, warfarins,
- 20 coumadin, coumarin, agents of the statin family, ticlopidine, statin agents, cerivastatine, simvastatin, lovastatin, agents of the statin family, cerivastatine (Baycol), simvastatin, lovastatin, etc.

- Examples of antithrombotic and/or non haemorrhagic formulations in the scope of
- 25 the present invention can be a combination of therapeutically effective amount of compound(s) of formula  $(CH_3)_3N^+(CH_2)_nCOO^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof and mixtures thereof, and therapeutically effective amount of one or more compound(s), pharmaceutically acceptable salts thereof, esters thereof, precursors thereof and
- 30 mixtures thereof, selected from the group consisting of:

anti aggregants as

abciximab, acetylsalicylate basic aluminium, acetylsalicylate carbonate sodium, acetylsalicylate lysine, acetylsalicylic acid, aloxiprine, anagrelide hydrochloride, 5 bencyclane furanate, carbasalate calcium, clopidogrel sulfate, epoprostenol sodium, epifibatide, hydroxychloroquine sulfate, iloprost, nicergoline, nifedipine, pyricarbate, sulfinpyrazone, ticlopidine hydrochloride, tirofiban hydrochloride, verapamil hydrochloride, and compounds structurally similar to one of the preceding anti aggregant compounds,

10

and/ or anticoagulants as

acenocoumarol, anisindione, bismacacetate ethyl, bromindione, coumatetral, dalteparin sodium, hirudin, xiran sulfate, enoxaparin sodium, fluindione, 15 heparinate magnesium, heparin calcium, heparin sodium, lepirudin nadroparin calcium, oxazindione, pentosan polysulfate, phenindione, phenprocoumon, reviparin sodium, tinzaparin sodium, ticlopidine, warfarin sodium, and compounds structurally similar to one of the preceding anti coagulant compounds,

20 

and/ or fibrinolytics as

alteplase, anistreplase, atorvastatin calcium, bromelains, ciprofibrate, defibrotide, fluvastatin sodium, glicazide, lovastatin, lys-plasminogen, phenformin, pravastatin sodium, reteplase, simvastatin, streptokinase, urokinase, and 25 compounds structurally similar to one of the preceding fibrinolytic compounds.

These antithrombotic and/or non haemorrhagic formulations can be preparations for oral, rectal, parenteral, transdermal, extracorporeal, intracorporeal administration. For example, for said combinations, the weight ratio between [compound(s) of formula 30  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof and mixtures thereof] / [anti

or by subcutaneous injection, while the other active agent is administered by oral way or by injection (subcutaneous, venous). When the combined pharmaceutical form is administered using the same administration way, the dosage form is advantageously an injectable form (such as a venous injectable form), but is preferably a oral dosage form, most preferably a solid or semi-solid dosage form. When using a dosage form, the active agent is advantageously in the form of pellets or micropellets or particles which are coated with a betaine containing layer. The coated particles or pellets can be further be coated with an enterosoluble coating which is gastric insoluble or placed in a matrix or capsule which is enterosoluble and gastric insoluble. Preferably, at least the glycine betaine is in a form suitable for subcutaneous injection (preferably intra venous injection) or in a form adapted for the preparation of a form suitable for subcutaneous injection (preferably intravenous injection).

The invention further relates to a process of treatment of a patient in need or for preventing troubles for a patient, by administering to said patient a therapeutic effective amount of an therapeutic active agent having at least one side effect selected among the group consisting of haemorrhagic events, coagulation troubles, thromboses and associations thereof, in which before and/or during and/or after said administration (preferably before and/or during) said patient is administered a therapeutic effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+-(\text{CH}_2)_n-\text{COO}^-$ , with  $n$  an integer from 1 to 5, preferably equal to 1, for preventing at least 50%, advantageously at least 75%, preferably at least 90%, most preferably substantially completely said troubles and/or for reducing the seriousness of said side effect, advantageously of a factor of at least 50%, preferably of at least 75%, most preferably of at least 90%, especially substantially completely. Glycine betaine is preferably subcutaneous injected (most preferably intravenous injection)

The present invention relates to a controlled release preparation or device of betaine and, to processes for its preparation and to its medical use. In particular, the invention relates to a controlled release preparation comprising betaine, preferably glycine betaine or a pharmaceutically acceptable salt thereof.

Betaine is a compound of formula  $(\text{CH}_3)_3 \text{N}^+ (\text{CH}_2)_n \text{COO}^-$  with  $n$  being advantageously an integer of 1 to 5. Conventional preparations in the form of syrup, or powder have been commercially available for many years for use in the treatment of homocystinuria. Such preparations, however, do not provide a controlled release of the betaines. Moreover, despite 's long-standing use, controlled release preparations for oral, rectal, parenteral, transdermal, extracorporal, intracorporal administration containing as active ingredient a betaine have not even previously been described, nor suggested in the literature.

10

It is an object of the present invention to provide an oral, rectal, parenteral, transdermal, extracorporal, intracorporal controlled release of a betaine, preferably glycine betaine preparation suitable for at least 5 minutes, such as for at least 10 minutes, ...twelve-hourly (e.g. up to twenty-four hourly or even more, such as for a week, two weeks, one month, three months ) administration for the treatment of a mammalian.

The present invention therefore provides a controlled release preparation and/or device comprising betaine, preferably glycine betaine or a pharmaceutically acceptable salt thereof or ester thereof for body (oral, rectal, parenteral, transdermal, extracorporal, intracorporal, etc.) administration.

Suitable pharmaceutically acceptable salts of betaine, preferably glycine betaine for use according to the present invention are those conventionally known in the art such as pharmaceutically acceptable acid addition salts. The anhydrous salt is particularly preferred.

The invention relates to a controlled release pharmaceutical system suitable for delivering in a controlled manner to the bloodstream of a mammalian a betaine or an effective amount of a compound of formula  $(\text{CH}_3)_3 \text{N}^+ (\text{CH}_2)_n \text{COO}^-$  with  $n$  an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof,

30

esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof, and/or to

a controlled release pharmaceutical system suitable for delivering in a controlled manner to the bloodstream of a mammalian as active ingredient at least a compound  
5 selected from the group consisting of betaines or an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof.

The system of the invention is an oral controlled release preparation or device and/or  
10 a transdermal controlled release preparation and/oral transdermal controlled release device

a parenteral controlled release preparation and/or an extracorporal controlled release device and/or an intracorporal controlled release device or preparation and/or is a rectal controlled release preparation and/or a rectal controlled release device and/or a  
15 mucous controlled release preparation or device and/or a pulmonary controlled release preparation or device and/or an ocular controlled release preparation or device.

According to an embodiment, the system combines at least two systems selected from the group consisting of: oral controlled release preparations, oral controlled  
20 release device, transdermal controlled release preparations, transdermal controlled release devices, parenteral controlled release preparations, parenteral controlled release devices, extracorporal controlled release preparations, extracorporal controlled release devices, intracorporal controlled release preparations, intracorporal controlled release devices, rectal controlled release preparations, rectal controlled  
25 release device, a mucous controlled release preparations, mucous controlled release devices, pulmonary controlled release preparations, pulmonary controlled release devices, ocular controlled release preparations and ocular controlled release devices.

In the system of the invention the active ingredient is preferably glycine betaine.

30 The invention relates also to a controlled release pharmaceutical system for releasing an effective therapeutically amount of at least a compound selected from the group

consisting of betaines or an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof, for treating or preventing blood flow disturbances, and

- 5 to a controlled release pharmaceutical system for releasing an effective therapeutic amount of at least a compound selected from the group consisting of betaines, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof, for treating or preventing thrombosis and/or thromboembolic disorders.

10

The system of the invention is advantageously a system controlling at least for 10 minutes, advantageously at least for 15 minutes, preferably at least for 30 minutes, the release of at least a compound selected from the group consisting of betaines or an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an

15 integer from 1 to 5,, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof.

Preferably, the system controls at least for 60 minutes, advantageously at least for 90 minutes, preferably at least for 120 minutes, the release of at least a compound selected from the group consisting of betaines or an effective amount of a compound

20 of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5,, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof.

Most preferably the system controls at least for 180 minutes, advantageously at least for 240 minutes, preferably at least for 360 minutes, most preferably at least for 1440

25 minutes (for example for 1 week, for two weeks, for one month), the release of at least a compound selected from the group consisting of betaines or an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5,, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof.

According to a possible embodiment, the system and/or the device of the invention comprises one or more electronic device or chips controlling one or more releasing system or device, such as a micro pump(s), a syringe, a balloon, etc.

The invention further relates to the use of betaine, a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5,, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof, for the preparation of a system of the invention and/or to a method for treating or preventing a blood flow disturbance, in which a betaine or a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof is administered in a controlled manner to the blood stream of a mammalian, and/or to a method for for treating or preventing thrombosis and/or thromboembolic disorders, in which a betaine or a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, precursors thereof, and mixtures thereof is administered in a controlled manner to the blood stream of a mammalian.

An example of oral controlled release preparation according to the present invention is one that achieves slow release of a drug over an extended period of time, thereby extending the duration of drug action over that achieved by conventional delivery. Preferably such a preparation maintains a drug concentration in the blood within the therapeutic range for 12 hours or more, most preferably for 24 hours or more.

The present inventor has found that in order to allow for controlled release betaine, preferably glycine betaine over at least a twelve hour period following oral administration, the in vitro release rate preferably corresponds to the following % rate of betaine, preferably glycine betaine released:

TABLE 1

TIME (H)	% RELEASED
1	0-50



	2	0-75
	4	3-95
	8	10-100
	12	20-100
5	16	30-100
	24	50-100
	36	>80

---

10

Another preferred preparation especially suited for twice-a-day dosing has an in vitro release rate corresponding to the following % rate of betaine, preferably glycine betaine released:

TABLE 2

15

---

TIME (H)	% RELEASED
----------	------------

---

	1	20-50
	2	40-75
20	4	60-95
	8	80-100
	12	90-100

---

25

Yet another preferred preparation particularly suited for once-a-day dosing has an in-vitro release rate corresponding to the following % rate of betaine, preferably glycine betaine released:

TABLE 3

30

---

TIME (H)	% RELEASED
----------	------------

---

	1	0-50
	2	0-75

25

	4	10-95
	8	35-100
	12	55-100
	16	70-100
5	24	>90

---

A still farther preferred preparation in accordance with the invention also particularly suited for once-a-day dosing has an in vitro release rate corresponding to the following % rate of betaine, preferably glycine betaine released.

TABLE 4

	TIME (H)	% RELEASED
15	1	0-30
	2	0-40
	4	3-55
	8	10-65
	12	20-75
20	16	30-88
	24	50-100
	36	>80

---

More preferably a preparation for once-a-day dosing has an in vitro release rate substantially as follows;

	TIME (H)	% BETAINE, PREFERABLY GLYCINE BETAINE RELEASED
30	1	15-25
	2	25-35

4	30-45
8	40-60
12	55-70
16	60-75

5

---

Another preferred dissolution rate in vitro upon release of the controlled release preparation for administration twice daily according to the invention, is between 5  
10 and 50% (by weight) betaine, preferably glycine betaine released after 1 hour, between 10 and 75% (by weight) betaine, preferably glycine betaine released after 2 hours, between 20 and 95% (by weight) betaine, preferably glycine betaine released after 4 hours, between 40 and 100% (by weight) betaine, preferably glycine betaine released after 8 hours, more than 50% (by weight) betaine, preferably glycine betaine  
15 released after 12 hours, more than 70% (by weight) released after 18 hours and more than 80% (by weight) betaine, preferably glycine betaine released after 24 hours.

Furthermore, it is preferred in the case of a controlled release preparation for  
20 administration twice daily that after 8 hours following oral administration between 70 and 95% (by weight) betaine, preferably glycine betaine is absorbed in vivo, between 77 and 97% (by weight) betaine, preferably glycine betaine is absorbed after 10 hours and between 80 and 100% (by weight) betaine, preferably glycine betaine is absorbed after 12 hours.

25

A formulation in accordance with the invention suitable for twice-a-day dosing may have a  $t_{max}$  of 1.5 to 8 hours, preferably 2 to 7 hours, and a  $W_{sub.50}$  value in the range 7 to 16 hours.

30

A formulation in accordance with the invention suitable for once-a-day dosing may have a  $t_{max}$  in the range of 3 to 6 hours, preferably 4 to 5 hours and a  $W_{sub.50}$  value in the range of 10 to 36 hours.

5

The  $W_{sub.50}$  parameter defines the width of the plasma profile at 50%  $C_{max}$ , i.e. the duration over which the plasma concentrations are equal to or greater than 50% of the peak concentration. The parameter is determined by linear interpolation of the observed data and represents the difference in time between the first (or only)  
10 upslope crossing and the last (or only) downslope crossing in the plasma profile.

The in vitro release rates mentioned herein can be are, except where otherwise specified, those obtained by measurement using the Ph. Eur. Paddle Method. at 100  
15 rpm in 900 ml 0.1N hydrochloric acid at 37.degree. C. and using any suitable method for detecting the betaine or glycine betaine (such as HPLC, UV detection, etc.,).

The in vivo absorption rate is determined from measurement of plasma concentration against time using the deconvolution technique. A conventional release betaine,  
20 preferably glycine betaine drop preparation (Tramal (trade mark), Grunenthal) was used as the weighting-function and the elimination half life of betaine, preferably glycine betaine was taken as 7.8 hours.

The controlled release preparation according to the invention preferably contains an  
25 effective amount of betaine, preferably glycine betaine or a pharmaceutically acceptable salt or esters thereof, precursors thereof, precursors thereof, conveniently in the range of from 50 to 8000 mg, especially 100, 200, 300, 400 to 600, 800 to 1000, 1500 to 5000 mg (calculated as betaine, preferably glycine betaine anhydrous) per dosage unit.

30

The controlled release preparation according to the invention may be presented, for example, as granules, spheroids, pellets, multiparticulates, capsules, tablets, sachets, controlled release suspensions, or in any other suitable dosage form incorporating such granules, spheroids, pellets or multiparticulates.

5

The active ingredient in the preparation according to the invention may suitably be incorporated in a matrix. This may be any matrix that affords controlled release betaine, preferably glycine betaine over at least a twelve hour period and preferably that affords in-vitro dissolution rates and in vivo absorption rates of betaine, preferably glycine betaine within the ranges specified above. Preferably the matrix is a controlled release matrix. Alternatively, normal release matrices having a coating which provides for controlled release of the active ingredient may be used.

Suitable materials for inclusion in a controlled release matrix include

15

(a) Hydrophilic or hydrophobic polymers, such as gums, cellulose ethers, acrylic resins and protein derived materials. Of these polymers, the cellulose ethers, especially alkylcelluloses are preferred. The preparation may conveniently contain between 1% and 80% (by weight) of one or more hydrophilic or hydrophobic polymers.

20

(b) Digestible, long chain ( $C_8$  - $C_{50}$ , especially  $C_{12}$  - $C_{40}$ ), substituted or unsubstituted hydrocarbons, such as fatty acids, fatty alcohols, glyceryl esters of fatty acids, mineral and vegetable oils and waxes. Hydrocarbons having a melting point of between 25.degree. and 90.degree. C. are preferred. Of these long chain hydrocarbon materials, fatty (aliphatic) alcohols are preferred. The preparation may conveniently contain up to 60% (by weight) of at least one digestible, long chain hydrocarbon.

25

(c) Polyalkylene glycols. The preparation may suitably contain up to 60% (by weight) of one or more polyalkylene glycols.

30

One particularly suitable controlled release matrix comprises one or more alkylcelluloses and one or more C<sub>12</sub> -C<sub>36</sub> aliphatic alcohols. The alkylcellulose is preferably C<sub>1</sub> -C<sub>6</sub> alkyl cellulose, especially ethyl cellulose. The controlled release preparation according to the invention preferably contains from 1 to 20% (by weight), especially from 2 to 15% (by weight) of one or more alkylcelluloses.

The aliphatic alcohol may conveniently be lauryl alcohol, myristyl alcohol or stearyl alcohol but is preferably cetyl alcohol or more preferably cetostearyl alcohol. The controlled release preparation suitably contains from 5 to 30% (by weight) of aliphatic alcohol, especially from 10 to 25% (by weight) of aliphatic alcohol.

Optionally the controlled release matrix may also contain other pharmaceutically acceptable ingredients which are conventional in the pharmaceutical art such as diluents, lubricants, binders, granulating aids, colorants, flavorants, surfactants, pH adjusters, anti-adherents and gildants, e.g. dibutyl sebacate, ammonium hydroxide, oleic acid and colloidal silica.

The controlled release preparation according to the invention may conveniently be film coated using any film coating material conventional in the pharmaceutical art. Preferably an aqueous film coating is used.

Alternatively, the controlled release preparation according to the invention may comprise a normal release matrix having a controlled release coating. Preferably the preparation comprises film coated spheroids containing the active ingredient and a spheronising agent.

The spheronising agent may be any suitable pharmaceutically acceptable material which may be spheronised together with the active ingredient to form spheroids. A preferred spheronising agent is microcrystalline cellulose. The microcrystalline cellulose used may suitably be, for example, Avicel PH 101 or Avicel PH 102 (Trade Marks, FMC Corporation).

Optionally the spheroids may contain other pharmaceutically acceptable ingredients conventional in the pharmaceutical art such as binders, bulking agents and colorants. Suitable binders include water soluble polymers, water soluble hydroxyalkyl  
5 celluloses such as hydroxypropylcellulose or water insoluble polymers (which may also contribute controlled release properties) such as acrylic polymers or copolymers for example ethylcellulose. Suitable bulking agents include lactose.

The spheroids are coated with a material which permits release of the active  
10 ingredient at a controlled rate in an aqueous medium. Suitable controlled release coating materials include water insoluble waxes and polymers such as polymethacrylates (for example Eudragit polymers, Trade Mark) or water insoluble celluloses, particularly ethylcellulose. Optionally, water soluble polymers such as polyvinylpyrrolidone or water soluble celluloses such as  
15 hydroxypropylmethylcellulose or hydroxypropylcellulose may be included. Optionally other water soluble agents such as polysorbate 80 may be added.

Alternatively the drug may be coated onto inert non-pareil beads and the drug loaded  
20 beads coated with a material which permits control of the release of the active ingredient into the aqueous medium.

In a further aspect the present invention provides a process for preparing a controlled release preparation according to the present invention comprising incorporating betaine, preferably glycine betaine or a pharmaceutically acceptable salt thereof in a  
25 controlled release matrix:

- (a) granulating a mixture comprising betaine, preferably glycine betaine or a pharmaceutically acceptable salt thereof and one or more alkylcelluloses,
- 30 (b) mixing the alkylcellulose containing granules with one or more C.sub.12-36 aliphatic alcohols; and optionally

- (c) shaping and compressing the granules, and film coating, if desired; or
- (d) granulating a mixture comprising betaine, preferably glycine betaine or a  
5 pharmaceutically acceptable salt thereof, lactose and one or more alkylcelluloses  
with one or more C.sub.12-36 aliphatic alcohol; and, optionally,
- (e) shaping and compressing the granules, and film coating, if desired.
- 10 The controlled release preparation according to the invention may also be prepared in  
the form of film coated spheroids by  
granulating the mixture comprising betaine, preferably glycine betaine or a  
pharmaceutically acceptable salt thereof and a spheronising agent;  
extruding the granulated mixture to give an extrudate;  
15 spheronising the extrudate until spheroids are formed; and  
coating the spheroids with a film coat.
- One preferred form of unit dose form in accordance with the invention comprises a  
capsule filled with controlled release particles essentially comprising the active  
20 ingredient, a hydrophobic fusible carrier or diluent and optionally a hydrophilic  
release modifier. In particular, the controlled release particles are preferably prepared  
by a process which comprises forming a mixture of dry active ingredient and fusible  
release control materials followed by mechanically working the mixture in a high  
speed mixer with an energy input sufficient to melt or soften the fusible material  
25 whereby it forms particles with the active ingredient. The resultant particles, after  
cooling, are suitably sieved to give particles having a size range from 0.1 to 3.0 mm,  
preferably 0.25 to 2.0 mm. An example according to the invention is described below  
which is suitable for the commercial production of dosage units.
- 30 When using such a processing technique it has been found that, in order most readily  
to achieve the desired release characteristics (both in vivo and in vitro as discussed



above) the composition to be processed should comprises two essential ingredients namely:

betaine, preferably glycine betaine or salt thereof; and

hydrophobic fusible carrier or diluent; optionally together with

- 5 a release control component comprising a water-soluble fusible material  
or a particulate soluble or insoluble organic or inorganic material.

The inventor found that the total amount of betaine, preferably glycine betaine or pharmaceutically acceptable salt thereof in the composition may vary within wide  
10 limits, for example from 10 to 90% by weight thereof.

The hydrophobic fusible component (b) should be a hydrophobic material such as a natural or synthetic wax or oil, for example hydrogenated vegetable oil, hydrogenated castor oil, microcrystalline wax, Beeswax, Carnauba wax or glyceryl  
15 monostearate, and suitably has a melting point of from 35.degree. to 140.degree. C., preferably 45.degree. to 110.degree. C.

The release modifying component (c), when a water soluble fusible material, is conveniently a polyethylene glycol and, when a particulate material, is conveniently  
20 a pharmaceutically acceptable material such as dicalcium phosphate or lactose.

Another preferred process for the manufacture of a formulation in accordance with the invention comprises

- 25 (a) mechanically working in a high-speed mixer, a mixture of betaine, preferably glycine betaine or a pharmaceutically acceptable salt in particulate form and a particulate, hydrophobic fusible carrier or diluent having a melting point from 35.degree. to 140.degree. C. and optionally a release control component comprising a water soluble fusible material, or a particulate soluble or insoluble organic or  
30 inorganic material at a speed and energy input which allows the carrier or diluent to melt or soften, whereby it forms agglomerates,

- (b) breaking down the larger agglomerates to give controlled release seeds; and  
(c) continuing mechanically working with optionally a further addition of low percentage of the carrier or diluent.
- 5 optionally repeating steps (c) and possibly (b) one or more times.

This process is capable of giving a high yield (over 80%) of particles in a desired size range, with a desired uniformity of release rate of betaine, preferably glycine betaine or salt thereof.

- 10 The resulting particles may be sieved to eliminate any over-or undersized material then formed into the desired dosage units by for example, encapsulation into hard gelatin capsules containing the required dose of the active substance or by compression into tablets.
- 15 In this method in accordance with the invention preferably all the betaine, preferably glycine betaine or salt thereof is added in step (a) together with a major portion of the hydrophobic fusible release control material used. Preferably the amount of fusible release control material added in step (a) is between 10% and 90% w/w of the total amount of ingredients added in the entire manufacturing operation, more preferably
- 20 between 20% and 70% w/w.

- Stage (a) of the process may be carried out in conventional high speed mixers with a standard stainless steel interior, e.g. a Collette Vactron 75 or equivalent mixer. The mixture is processed until a bed temperature about 40.degree. C. or above is achieved
- 25 and the resulting mixture acquires a cohesive granular texture, with particle sizes ranging from about 1-3 mm to fine powder in the case of non-aggregated original material. Such material, in the case of the embodiments described below, has the appearance of agglomerates which upon cooling below 40.degree. C. have structural integrity and resistance to crushing between the fingers. At this stage the
- 30 agglomerates are of an irregular size, shape and appearance.

The agglomerates are preferably allowed to cool. The temperature to which it cools is not critical and a temperature in the range room temperature to 37.degree. C. may be conveniently used.

5

The agglomerates are broken down by any suitable means, which will comminute oversize agglomerates and produce a mixture of powder and small particles preferably with a diameter under 2 mm. It is currently preferred to carry out the classification using a Jackson Crockatt granulator using a suitable sized mesh, or a  
10 Comil with an appropriate sized screen. It was found that if too small a mesh size is used in the aforementioned apparatus the agglomerates melting under the action of the beater or impeller will clog the mesh and prevent further throughput of mixture, thus reducing yield. A mesh size of 12 has been found adequate.

15 The classified material is returned to the high speed mixer and processing continued. It is believed that this leads to cementation of the finer particles into particles of uniform size range.

In one preferred form of the method of the invention processing of the classified  
20 materials is continued, until the hydrophobic fusible materials used begin to soften/melt and optionally additional hydrophobic fusible material is then added. Mixing is continued until the mixture has been transformed into particles of the desired predetermined size range.

25 In order to ensure uniform energy input into the ingredients in the high speed mixer it is preferred to supply at least part of the energy by means of microwave energy.

Energy may also be delivered through other means such as by a heating jacket or via the mixer impeller and chopper blades.

After the particles have been formed they are cooled or allowed to cool, and may then be sieved to remove any over or undersized material.

The resulting particles may be used to prepare dosage units in accordance with the invention in the form of e.g. tablets or capsules in manners known per se.

The inventor have also found that particles containing betaine, preferably glycine betaine or a salt thereof produced by a melt processing as described in application PCT/SE93/00225 and the process described and claimed in our prior unpublished UK application No. 9324045.5 filed on 23 Nov. 1993 as well as the process described herein are particularly useful for processing into the form of tablets.

The inventor found that by suitable selection of the materials used in forming the particles and in the tableting and the proportions in which they are used, enables a significant degree of control in the ultimate dissolution and release rates of the betaine, preferably glycine betaine or salt thereof from the compressed tablets.

Usually, to form a tablet in accordance with the invention, particles prepared as described above will be admixed with tableting excipients e.g. one or more or the standard excipients such as diluents, lubricants, binding agents, flow aids, disintegrating agents, surface active agents or water soluble polymeric materials.

Suitable diluents are e.g. microcrystalline cellulose, lactose and dicalcium phosphate. Suitable lubricants are e.g. magnesium stearate and sodium stearyl fumarate. Suitable binding agents are e.g. hydroxypropyl methyl cellulose, polyvidone and methyl cellulose.

Suitable disintegrating agents are starch, sodium starch glycolate, crospovidone and croscarmallose sodium. Suitable surface active are Poloxamer 188.RTM., polysorbate 80 and sodium lauryl sulfate. Suitable flow aids are talc colloidal anhydrous silica.

Suitable water soluble polymers are PEG with molecular weights in the range 1000 to 6000.

- 5 To produce tablets in accordance with the invention, particles produced in accordance with the invention may be mixed or blended with the desired excipient(s), if any, using conventional procedures, e.g. using a Y-Cone or bin-blender and the resulting mixture compressed according to conventional tableting procedure using a suitable size tableting mold. Tablets can be produced using conventional tableting  
10 machines, and in the embodiments described below were produced on standard single punch F3 Manesty machine or Kilian RLE15 rotary tablet machine.

Generally speaking I find that even with such a highly water soluble active agent as betaine, preferably glycine betaine or salt thereof tablets formed by compression  
15 according to standard methods give very low release rates of the active ingredient e.g. corresponding to release over a period of greater than 24 hours, say more than 36. The inventor found that the release profile can be adjusted in a number of ways. For instance a higher loading of the drug will be associated with increased release rates; the use of larger proportions of the water soluble fusible material in the  
20 particles or surface active agent in the tableting formulation will also be associated with a higher release rate of the active ingredient. By controlling the relative amounts of these ingredients it is possible to adjust the release profile of the betaine, preferably glycine betaine or salt thereof.

- 25 The following examples illustrate various aspects of the present invention. They are not to be construed to limit the claims in any manner whatsoever.

#### **APPARATUS AND METHOD**

30 **MATERIAL**

Betaine anhydrous, BETAFIN ® ( Finnsugar Bioproducts, CULTOR, Helinski )

Rats Wistar, males, weight between 250 and 300 grams

Sodium Thiopental

Aggregometer CHRONOLOG COULTRONIC S.A. France

5 ADP & collagen Laboratoires Stago France

## METHODS

The aggregation is made in accordance to the methods Cardinal & Flower.  
10 Pharmacol. Method. 1980 . and to American Journal of Clinical Pathology, 1989;  
92: 676-679. Sureney. JD. Whole Blood aggregometry.

After a keeping period of 8 days, the rats are subjected to a fasting for 12 hours.  
Betaine is subcutaneous injected one hour before blood sampling. The rats are then  
anaesthetised with sodium Thiopental administered at a dose of 200mg/Kg and the  
15 blood samples are taken by intracardiac puncture on a trisodium citrate solution ( 1  
volume of solution at 3,8 % citrate for 9 volumes of blood).

### Activated coagulation time ( kaolin )

20 This test explores the intrinsic coagulation pathway. One hour after sub cutaneous  
administration of the betaine, 0.8 ml total blood by intracardiac way is injected in a  
container HR, HemoTec. These tubes contain the kaolin activator. ( Method  
HemoTec., automated coagulation timer manufactured by MEDTRONIC  
HEMOTEC Inc., Englewood, CO., USA).

25

### Induced haemorrhagic time IHT

( E. Dejana. Bleeding time in rats . Thrombosis. Rech. 1982 )

Blood samples are made before the test. The tail of anaesthetised rat, is dipped for 5  
minutes in a water bath at 37°C so as to provoke a dilatation of the peripheral vessels  
30 which are removed and cut at the end, the chronometer being started. The IHT is  
defined as being the time period comprised between the cutting of end tail and the

end of the haemorrhage or bleeding. The end of haemorrhage is defined as the time where the last drop of blood is removed from the tail and no other drop is seen during 180 seconds. The substances were subcutaneously administrated 60 minutes prior to the tail cut.

5

#### A/ Principle of laser-induced thrombosis

(Seiffge D. et al., 1989; Weichter W. et al., 1983)

In this model, lesion of the vascular wall is induced by a laser beam. This beam causes a limited lesion of the vascular endothelium (only 1 to 2 cells are destroyed). This laying bare of the sub-endothelium, which is a thrombogenic surface, results in the adherence of platelets via glycoprotein IIb/IIIa. This adherence of platelets is followed by the activation thereof. They form pseudopods and secrete the content of their granules. This activation results in the appearance of glycoproteins IIb/IIIa which are necessary for the aggregation of the platelets between them. This lesion is induced in the mesenteric microcirculation of the rat. It is immediately followed by the formation of a thrombus (in a few seconds). This thrombus, which rapidly enlarges under the influence of the flow of blood, embolises before being formed again.

20

By this means, the assessment of the effect of glycine betaine was conducted pharmacologically in conjunction with the study of two active molecules used as a reference; namely acetylsalicylic acid and heparin (of low molecular weight). The assessment also involved the activity of glycine betaine in relation to the prothrombotic effects induced by contrasting products.

25

#### B / Stasis-induced thrombosis

A laparotomy was performed to open the lower vena cava, on which a ligature was placed at  $T_0$ , followed by subcutaneous injection of glycine betaine at  $T_0 + 2$  hours, followed by withdrawal of the clot and blood samples at  $T_0 + 6$  hours.

30

**C/ Experimental procedure**

Male Wistar rats were used for these tests. They weighed between 200 and 250 grams. After an 8-day stabilisation period, the rats were subjected to fasting for 12 hours. They were then anaesthetised, glycine betaine was administered subcutaneously, and the mesentery (laser) or vena cava (stasis) was opened at the end of the experiments.

**EXAMPLES:**

10

**Example1: Evaluation of the number of emboles and the duration of embolisation after vascular change due to laser firings.**

	<b>Number of emboles or embolies</b>	<b>Duration of embolisation (minutes)</b>
<b>Negative control NaCl 0.9%</b>	5.33 $\pm$ 0.58	2 $\pm$ 0
<b>Glycine betaine 5 mg/kg</b>	2 $\pm$ 0	1 $\pm$ 0
<b>Acetylsalicylic acid 100 mg/kg</b>	1 $\pm$ 1	0.33 $\pm$ 0.58
<b>Heparin 2 mg/kg</b>	2.67 $\pm$ 0.52	1 $\pm$ 0

15 Glycine betaine considerably reduced the number of emboles and the duration of embolisation after vascular change due to laser firings. The results demonstrate its powerful anti-thrombotic activity.

**Example2: Evaluation of the bleeding time caused**

20 ( E. Dejana. Bleeding time in rats. Thrombosis. Rech. 1982)

	<b>Bleeding time (seconds)</b>
<b>Negative control NaCl 0.9%</b>	101.52 $\pm$ 5.7



40

<b>Glycine betaine 5 mg/kg</b>	<b>95 ± 5</b>
<b>Acetylsalicylic acid 100 mg/kg</b>	<b>276.67 ± 20.82</b>
<b>Heparin 2 mg/kg</b>	<b>313.33 ± 20</b>

- These results show that glycine betaine maintains the bleeding time which is caused within the values of the negative control. In addition to its anti-thrombotic activity, glycine betaine does not result in any risk of haemorrhage compared with the positive controls.

**Example 3: Evaluation of platelet aggregation after vascular change due to laser firings**

(Cardinal & Flower, Pharmacol. Method. 1980)

	<b>Amplitude (ohms)</b>	<b>Velocity (ohms/min)</b>
<b>Negative control NaCl 0.9%</b>	<b>13 ± 1</b>	<b>9 ± 1</b>
<b>Glycine betaine 5 mg/kg</b>	<b>0.66 ± 1.15</b>	<b>1.66 ± 1.15</b>
<b>Acetylsalicylic acid 100 mg/kg</b>	<b>2.33 ± 2.08</b>	<b>2 ± 1</b>
<b>Heparin 2 mg/kg</b>	<b>4.33 ± 0.57</b>	<b>2.66 ± 0.50</b>

- 10 These results demonstrate the anti-aggregation effect of glycine betaine.

**Example 4: Evaluation of the effect on blood cells**

**a / Platelet count**

	<b>Number of platelets (10<sup>9</sup>)</b>
<b>Negative control NaCl 0.9%</b>	<b>788 ± 30.14</b>
<b>Glycine betaine 5 mg/kg</b>	<b>804.67 ± 20.03</b>
<b>Acetylsalicylic acid 100 mg/kg</b>	<b>855.33 ± 63.17</b>
<b>Heparin 2 mg/kg</b>	<b>777.33 ± 6.43</b>

**b/ White corpuscle count**

	Number of white corpuscles ( $10^9$ )
Negative control NaCl 0.9%	$5.03 \pm 1$
<b>Glycine betaine 5 mg/kg</b>	$4.43 \pm 0.32$
<b>Acetylsalicylic acid 100 mg/kg</b>	$4.33 \pm 1.00$
<b>Heparin 2 mg/kg</b>	$5.80 \pm 0.10$

**c/ Red corpuscle count**

	Number of red corpuscles ( $10^{12}$ )
Negative control NaCl 0.9%	$6.56 \pm 0.15$
<b>Glycine betaine 5 mg/kg</b>	$6.19 \pm 0.25$
<b>Acetylsalicylic acid 100 mg/kg</b>	$6.15 \pm 0.31$
<b>Heparin 2 mg/kg</b>	$6.20 \pm 0.20$

- 5 The counts of the elements occurring in the blood remained within the values of the negative control and demonstrated the innocuousness of glycine betaine

**Example 5: Biological Balance****a/ Quick time**

	QT (seconds)
Negative control NaCl 0.9%	$17 \pm 1$
<b>Glycine betaine 5 mg/kg</b>	$16.9 \pm 1.05$
<b>Acetylsalicylic acid 100 mg/kg</b>	$18.33 \pm 2.08$
<b>Heparin 2 mg/kg</b>	$29.50 \pm 0.52$

**b / Activated cephaline time (ACT)**

	<b>ACT (seconds)</b>
Negative control NaCl 0.9%	20.5 ± 0.5
<b>Glycine betaine 5 mg/kg</b>	39.9 ± 1.05
<b>Acetylsalicylic acid 100 mg/kg</b>	27.26 ± 1.1
<b>Heparin 2 mg/kg</b>	39.46 ± 1.36

**c/ Fibrinogen analysis**

	<b>Fibrinogen (g/l)</b>
Negative control NaCl 0.9%	2.45 ± 0.19
<b>Glycine betaine 5 mg/kg</b>	1.7 ± 0.1
<b>Acetylsalicylic acid 100 mg/kg</b>	2.19 ± 0.33
<b>Heparin 2 mg/kg</b>	2.13 ± 0.25

5

**d/ Alpha<sub>2</sub>-antiplasmin analysis (α<sub>2</sub>AP)**

	<b>α<sub>2</sub>AP (%)</b>
Negative control NaCl 0.9%	30.16 ± 0.85
<b>Glycine betaine 5 mg/kg</b>	29.7 ± 0.68
<b>Acetylsalicylic acid 100 mg/kg</b>	29.36 ± 0.92
<b>Heparin 2 mg/kg</b>	29.4 ± 1.01

**e / Antithrombin III analysis (AT III)**

	<b>AT III (%)</b>
Negative control NaCl 0.9%	86 ± 3
<b>Glycine betaine 5 mg/kg</b>	89.5 ± 1.37
<b>Acetylsalicylic acid 100 mg/kg</b>	85.33 ± 3.51
<b>Heparin 2 mg/kg</b>	77.66 ± 1.52

**Example 6: Evaluation of the activity of glycine betaine as a function of time**

- 5    **Experimental groups:**      The product was tested at 5 mg/kg  
Laser-induced thrombosis

Control	NaCl 0,9%
Group I	The product was injected 1 hour before the experiment
10    Group II	The product was injected 2 hours before the experiment
Group III	The product was injected 3 hours before the experiment
Group IV	The product was injected 4 hours before the experiment

**a)      Effect of the product tested (5 mg/ml/kg) on the bleeding time caused.**

15

<b>Group</b>	<b>B.T.C. (seconds)</b>
NaCl 0.9%	110 ± 21.2
<b>I</b>	105 ± 26.2
<b>II</b>	145 ± 15.52
<b>III</b>	115.5 ± 14.2
<b>IV</b>	120 ± 10.13

**b) Effect of the product tested (5 mg/ml/kg) on arterial thrombosis induced by laser beam**

Group	Number of firings	Number of emboles	Duration of embolisation (minutes)
NaCl 0.9%	$2.5 \pm 0.84$	$5.7 \pm 1.5$	$2.1 \pm 0.69$
I	$3.49 \pm 1.07$	$1.8 \pm 1.44$	$0.51 \pm 0.5$
II	$3.0 \pm 1.5$	$1.4 \pm 1.18$	$0.3 \pm 0.23$
III	$2.50 \pm 1.25$	$1.99 \pm 0.4$	$1.00 \pm 0.5$
IV	$2.7 \pm 1.0$	$2.2 \pm 0.69$	$1.5 \pm 0.6$

**c) Effect of the product tested (5 mg/kg) on platelet aggregation induced ex vivo.**

Group	Amplitude (Ohms)	Velocity (ohm/minute)
NaCl 0.9%	$24.23 \pm 0.5$	$14.4 \pm 2.3$
I	$11.33 \pm 3.08$	$8.2 \pm 0.2$
II	$13.2 \pm 3.5$	$9.3 \pm 1.8$
III	$12.7 \pm 4.1$	$8.7 \pm 1.3$
IV	$13 \pm 2.8$	$8.7 \pm 1.15$

**d) Evaluation of the effect of glycine betaine on coagulation factors after repeated administration on 5 days of treatment**

	ACT (seconds)	Quick time (seconds)	Fibrinogen g/l
Untreated control	$21.25 \pm 2.3$	$16.1 \pm 1.0$	$3.03 \pm 0.45$
Glycine betaine (5 mg/kg/day)	$39.3 \pm 2.3$	$19.8 \pm 1.2$	$2.2 \pm 0.1$

**Example 7: Evaluation of the effect of glycine betaine on venous thrombosis induced by stasis.**

**a) Effect of glycine betaine on clot weight**

	Clot weight (mg)
Untreated control	$4.033 \pm 2$
Glycine betaine (1 mg/kg)	$3.1 \pm 0.4$
Glycine betaine (2.5 mg/kg)	$1.63 \pm 0.76$
Glycine betaine (5 mg/kg)	$0.76 \pm 0.4$

**5 b) Evaluation of the effect of glycine betaine on plasminogenesis**

	Plasminogenesis %
NaCl 0.9%	$2.7 \pm 0.33$
Glycine betaine (5 mg/kg)	$1.66 \pm 0.58$
Glycine betaine (2.5 mg/kg)	$2 \pm 0.15$
Glycine betaine (1 mg/kg)	$2.44 \pm 0.58$

**c) Evaluation of the effect of glycine betaine on coagulation**

	ACT (seconds)	Quick time (seconds)	Fibrinogen g/l
Untreated control	$30.2 \pm 2.7$	$16.1 \pm 1.0$	$3.03 \pm 0.45$
Glycine betaine (1 mg/kg)	$29.1 \pm 2.3$	$16.2 \pm 1.2$	$2.63 \pm 0.3$
Glycine betaine (2.5 mg/kg)	$31.2 \pm 2.6$	$16.6 \pm 0.7$	$2.2 \pm 0.17$
Glycine betaine (5 mg/kg)	$33.5 \pm 1.9$	$15.6 \pm 0.4$	$2.32 \pm 0.33$

**d) Evaluation of the effect of glycine betaine on coagulation factors**

	<b>Anti Xa units/ml</b>	<b>Anti IIa units/ml</b>
<b>Glycine betaine (5 mg/kg)</b>	$0.35 \pm 0.15$	-
<b>Glycine betaine (2.5 mg/kg)</b>	$0.14 \pm 0.10$	-
<b>Glycine betaine (1 mg/kg)</b>	$0.08 \pm 0.1$	-

Treatment with glycine betaine inhibits the thrombo-embolic complications which are initiated by laser firings. In fact, treatment with glycine betaine before laser firings decreases the vascular adherence of platelets and the aggregation thereof.

Treatment with glycine betaine inhibits thrombo-embolic complications. In fact, treatment with glycine betaine before the induction of thrombosis exhibited a high antithrombotic potential with regard to all the parameters which come into play in the process of thrombus formation. Moreover, the results for the biological parameters demonstrate the complete innocuousness of glycine betaine, which, in contrast to the reference products used (aspirin and heparin), does not induce any bleeding effect or undesirable side effect. These features mean that glycine betaine, in addition to its demonstrated efficacy, can be administered to people at risk of haemorrhage as well as to people who would be subject to risk of sensitivity or allergy if given conventional antithrombotic treatments (haemophiliac, allergic). Glycine betaine does not cause thrombopenia or haemorrhagic disorders (Examples 2 & 4). The experimental results of Example 5c shows that there is a consumption of fibrinogen.

It should be noted that, under the same experimental conditions for the preservation of blood, glycine betaine appeared to possess a high anti-coagulant capacity compared with tubes containing heparin or EDTA. The effective dose of glycine betaine appeared to be between 3 and 5 mg per  
5 haemolysis tube. This experimental result demonstrates the high anticoagulant potential of glycine betaine. It can thus be claimed that glycine betaine can be used as an anticoagulant both for the treatment of the human body in vivo and for the preservation of blood ex vivo.

10 **Evaluation of the activity of glycine betaine compared with that of contrasting products**

In the context of our research on the anti-thrombotic effects, and in order to complement our preliminary work on the efficacy of glycine betaine, we  
15 evaluated the effect of glycine betaine on the increase of the thrombo-embolic risk associated with the use of contrasting products known for their prothrombotic capacities. The significance of this model is that it enables a direct observation to be made of the formation of a thrombus at the site of the vascular lesion. These results explain the occurrence of thrombotic occlusions  
20 during angioplasty, especially amongst patients whose endothelium is already damaged or injured. Coronary angioplasty causes a stripping of the endothelium, exposing collagen, elastin and the smooth muscle cells of the circulating blood, analogously to the experimental thrombosis model employed. Thus, there is a higher incidence of new thrombi amongst patients  
25 who have had a recent coronary thrombosis or who have an eccentric coronary plaque.

The administration of contrasting products reduces the number of white corpuscles, the number of red corpuscles and the number of platelets.  
30 Contrasting products interact with leukocytes, induce the liberation of leukotrienes, increase vascular permeability and exert a chemotactic effect.



Moreover, contrasting products act to control the expression of P-selectin and cause the adherence of white corpuscles to the vascular endothelium. It has been shown that the use of contrasting products is associated with the occurrence of thrombi in variable amounts depending on the product used.

5

Two contrasting products were studied Hexabrix® (ionic) and ® Iopamidol (non-ionic).

**Example 8: Evaluation of number of emboles and duration of embolisation after vascular changes caused by laser firings and administration of contrasting products**

	Number of emboles	Duration of embolisation (minutes)
Negative control NaCl 0.9%	5.33 ± 0.58	2 ± 0
<b>Hexabrix®</b>	8 ± 1	3.67 ± 0.58
<b>Iopamidol®</b>	11.67 ± 0.50	6.33 ± 0,52
<b>Glycine betaine 5mg/kg + Hexabrix®</b>	4 ± 1	2 ± 0
<b>Glycine betaine 5 mg/kg + Iopamidol®</b>	5.33 ± 0.58	2.33 ± 0.48

**Example 9: Evaluation of induced bleeding time (IBD)**

	IBD (seconds)
<b>Negative control NaCl 0.9%</b>	101.52 ± 5.7
<b>Hexabrix®</b>	195 ± 13.23
<b>Iopamidol®</b>	128 ± 7.64
<b>Glycine betaine 5 mg/kg + Hexabrix®</b>	150 ± 5
<b>Glycine betaine 5 mg/kg + Iopamidol®</b>	111 ± 6.60

This example shows a reduction of the induced bleeding time of contrasting agents, and an anti-haemorrhagic effect of the betaine.

**Example 10: Evaluation of platelet aggregation after vascular change due to laser firings**

	Amplitude (ohm)	Velocity (ohm/min)
Negative control NaCl 0.9%	$13 \pm 1$	$9 \pm 1$
Hexabrix <sup>®</sup>	$6 \pm 1$	$5.66 \pm 0.57$
Iopamidol <sup>®</sup>	$15 \pm 2.64$	$12.33 \pm 0.50$
Glycine betaine 5 mg/kg + Hexabrix <sup>®</sup>	$2 \pm 1$	$5 \pm 0$
Glycine betaine 5 mg/kg + Iopamidol <sup>®</sup>	$4.66 \pm 0.52$	$9.33 \pm 0.8$

**Example 11: Evaluation of the effect of glycine betaine on blood cells**

5 **a / Platelet count**

	Number of platelets ( $10^9$ )
Negative control NaCl 0.9%	$788.33 \pm 30.14$
Hexabrix <sup>®</sup>	$620 \pm 10$
Iopamidol <sup>®</sup>	$585.67 \pm 23.54$
Glycine betaine 5 mg/kg + Hexabrix <sup>®</sup>	$669.67 \pm 7.37$
Glycine betaine 5 mg/kg + Iopamidol <sup>®</sup>	$704.33 \pm 92.33$

**b/ White corpuscle count**

	<b>Number of white corpuscles (10<sup>12</sup>)</b>
Negative control NaCl 0.9%	5.03 ± 0.20
<b>Hexabrix®</b>	2.96 ± 0.21
<b>Iopamidol®</b>	3.06 ± 0.35
<b>Glycine betaine 5 mg/kg + Hexabrix®</b>	4.20 ± 0.1
<b>Glycine betaine 5 mg/kg + Iopamidol®</b>	3.9 ± 0.3

**5 c/ Red corpuscle count**

	<b>Number of red corpuscles (10<sup>9</sup>)</b>
Negative control NaCl 0.9%	6.56 ± 0.15
<b>Hexabrix®</b>	5.43 ± 0.47
<b>Iopamidol®</b>	5.5 ± 0.36
<b>Glycine betaine 5 mg/kg + Hexabrix®</b>	6.5 ± 0.15
<b>Glycine betaine 5 mg/kg + Iopamidol®</b>	6.6 ± 0.19

**Example 12: Biological balance****a/ Quick time**

	<b>QT (seconds)</b>
<b>Negative control</b> <b>NaCl 0.9%</b>	$17 \pm 1$
<b>Hexabrix®</b>	$24.13 \pm 1$
<b>Iopamidol®</b>	$28.1 \pm 0.75$
<b>Glycine betaine 5 mg/kg +</b> <b>Hexabrix®</b>	$16.36 \pm 0.56$
<b>Glycine betaine 5 mg/kg</b> <b>Iopamidol®</b>	$17.83 \pm 1.2$

**5 b/ Activated cephaline time (ACT)**

	<b>ACT (seconds)</b>
<b>Negative control</b> <b>NaCl 0.9%</b>	$20.5 \pm 0.5$
<b>Hexabrix®</b>	$49.3 \pm 1.85$
<b>Iopamidol®</b>	$41.33 \pm 0.8$
<b>Glycine betaine 5 mg/kg +</b> <b>Hexabrix®</b>	$25.4 \pm 0.61$
<b>Glycine betaine 5 mg/kg</b> <b>Iopamidol®</b>	$22.4 \pm 0.7$

**c/ Fibrinogen analysis**

	<b>Fibrinogen (g/l)</b>
<b>Negative control</b> <b>NaCl 0.9%</b>	$2.45 \pm 0.19$
<b>Hexabrix®</b>	$1.49 \pm 0.18$
<b>Iopamidol®</b>	$1.5 \pm 0.8$
<b>Glycine betaine 5 mg/kg +</b> <b>Hexabrix®</b>	$1.7 \pm 0.09$
<b>Glycine betaine 5 mg/kg</b> <b>Iopamidol®</b>	$1.9 \pm 0.1$

**d/ Alpha<sub>2</sub>-antiplasmin analysis ( $\alpha$ 2AP)**

	<b><math>\alpha</math>2AP (%)</b>
<b>Negative control NaCl 0.9%</b>	30.16 $\pm$ 0.85
<b>Hexabrix<sup>®</sup></b>	23.26 $\pm$ 1.06
<b>Iopamidol<sup>®</sup></b>	25.23 $\pm$ 0.95
<b>Glycine betaine 5 mg/kg + Hexabrix<sup>®</sup></b>	25.66 $\pm$ 0.09
<b>Glycine betaine 5 mg/kg Iopamidol<sup>®</sup></b>	28.13 $\pm$ 0.8

**e/ Antithrombin III analysis (AT III)**

	<b>AT III (%)</b>
<b>Negative control NaCl 0.9%</b>	86.3 $\pm$ 3
<b>Hexabrix<sup>®</sup></b>	81.63 $\pm$ 0.66
<b>Iopamidol<sup>®</sup></b>	70.6 $\pm$ 1.51
<b>Glycine betaine 5 mg/kg + Hexabrix<sup>®</sup></b>	79.1 $\pm$ 1.05
<b>Glycine betaine 5 mg/kg Iopamidol<sup>®</sup></b>	87.26 $\pm$ 0.98

- 5 Treatment with glycine betaine inhibits the thrombo-embolic complications associated with the use of contrasting products. In fact, treatment with glycine betaine, before or during the injection of contrasting products, reduces the adherence of platelets and their aggregation at vascular level. These results demonstrate the anti-thrombotic and thrombolytic effects of
- 10 glycine betaine. It should be noted that the contrasting products can have other side effects such as haemostasis in catheters and endothelial lesions due

to the administration procedures themselves. Glycine betaine remedies these undesirable effects.

#### CONCLUSION

- 5 Glycine betaine possesses the same, or even better, therapeutic features as those of the anticoagulants and anti-aggregants investigated (acetylsalicylic acid and heparin), whilst exhibiting no undesirable effects.

10 The superior performance as regards therapeutic efficacy of glycine betaine in relation to these two molecules (acetylsalicylic acid and heparin) is an incentive for the formulation of a drug containing glycine betaine as a therapeutically active ingredient, said drug being intended for the treatment of thromboses and thrombo-embolic diseases.

- 15 According the results presented above, this drug also exhibits anticoagulant, anti-aggregant and fibrinolytic indications. The demonstrated innocuousness of this molecule enables long-term treatments to be considered which do not necessitate biological monitoring.

- 20 Interest in the use of glycine betaine is based on the fact that it acts at several levels of haemostasis, i.e. it acts on platelet aggregation, coagulation and fibrinolysis. This activity is durable and prevents repeated administration, which constitutes a considerable improvement in relation to existing treatments. The administration of betaine does not induce any haemorrhagic  
25 risk or other side effects (e.g. heparin-induced thrombopenia), which constitutes a major advance in antithrombotic therapy.

**Example 13 : Aggregation induced with ADP**Final ADP concentration 5 $\mu$ M

	Amplitude (ohms)	Velocity (ohm/minute)
Control NaCl 0.9%	16.4 +/- 1.67	13.8 +/- 1.3
Glycine betaine 2.5 mg/kg	13 +/- 0.82	5.75 +/- 0.96
Glycine betaine 5 mg/kg	7.25 +/- 0.96	4.75 +/- 0.5
Glycine betaine 10 mg/kg	0 +/- 0	0 +/- 0

- 5 The dose effect of the betaine shows its action on the glycoprotein IIb IIIa site, the betaine competing in a dose dependant manner with the agonist (ADP).

**Example 14 : Aggregation induced with collagen**10 Collagen concentration 10  $\mu$ gr/ml

	Amplitude (ohms)	Velocity (ohm/minute)
Control NaCl 0.9%	16.75 +/- 0.96	9.75 +/- 0.98
Glycine betaine 2.5 mg/kg	13.75 +/- 0.96	9.25 +/- 2.63
Glycine betaine 5 mg/kg	5.5 +/- 1.29	4.5 +/- 1
Glycine betaine 10 mg/kg	1.5 +/- 1.29	2 +/- 0.82

The dose effect of the betaine shows its action on the glycoprotein IIb IIIa site, the betaine competing in a dose dependant manner with the agonist (Collagen).

**Example 15: Activated coagulation time (subcutaneous administration of betaine at different dosages)**

	Activated Coagulation time (seconds)	Provoked Haemorrhage time (seconds)
Control NaCl 0.9%	48	107
Glycine betaine 10 mg/kg	128	105
Glycine betaine 30 mg/kg	179	112
Glycine betaine 50 mg/kg	215	115

The activated coagulation time is four time higher at a concentration of 50  
5 mg/kg, while not having an effect on the PHT.

**Example 16 : Activated Coagulation Time after subcutaneous administration of betaine at 10 mg/kg after 24 hours**

	Provoked hemorrhage seconds	Activated coagulation time (seconds)
Control NaCl 0.9%	105 +/- 5	48.4 +/- 8.9
Betaine 10mg/kg	114 +/- 12.76	71 +/- 3.51

10 **Example 17: Parameters of Thrombosis induced by laser 24 hours after sub cutaneous administration of betaine at 10 mg/kg**



	Number of laser firing	Number of emboles	Embolisation time (minutes)
Control NaCl 0.9%	2.33 +/- 0.57	5.33 +/- 0.57	2 +/- 0
Betaine 10mg/kg	3.33 +/- 0.57	1 +/- 0	0 +/- 0

**Example 18 : Activated Coagulation Time after subcutaneous administration of betaine at 20 mg/kg after 24 hours**

5

	Provoked hemorrhage seconds	Activated coagulation time (seconds)
Control NaCl 0.9%	105 +/- 5	48.4 +/- 8.9
Betaine 20mg/kg	110 +/- 13.22	154.66 +/- 11.01

**Example 19 : Parameters of Thrombosis induced by laser 24 hours after sub cutaneous administration of betaine at 20 mg/kg**

10

	Number of laser firing	Number of emboles	Embolisation time (minutes)
Control NaCl 0.9%	2.33 +/- 0.57	5.33 +/- 0.57	2 +/- 0
Betaine 10mg/kg	3.33 +/- 0.57	0.66 +/- 0.57	0 +/- 0

**Example 20 : Kinetic of the activated coagulation time after oral administration of betaine at 50mg/kg**

	Induced hemorrhage seconds	Activated coagulation time (seconds)
Control NaCl 0.9%	105 +/- 5	48.4 +/- 8.9
Betaine 50mg/kg – 1 hour	120 +/- 5	96 +/- 11.27
Betaine 50mg/kg – 6 hours	111 +/- 3.6	124.66 +/- 9.29
Betaine 50mg/kg – 24 hours	113.33 +/- 18.92	64.66 +/- 7.37
Betaine 50mg/kg – 48 hours	109 +/- 8.54	55.66 +/- 7.02

5 **Example 21 : Kinetic of Parameters of Thrombosis induced by laser and effect at different time for the oral administration of betaine at 50 mg/kg**

	Number of laser firing	Number of emboles	Embolisation time (minutes)
Control NaCl 0.9%	2.33 +/- 0.57	5.33 +/- 0.57	2 +/- 0
Betaine 50mg/kg 1 hour	4 +/- 0	0 +/- 0	0 +/- 0
Betaine 50mg/kg 6 hours	3.66 +/- 0.57	2.33 +/- 0.57	1 +/- 0
Betaine 50mg/kg 24 hours	2.33 +/- 0.57	2.33 +/- 0.57	1 +/- 0
Betaine 50mg/kg 48 hours	2.33 +/- 0.57	4.33 +/- 0.57	2 +/- 0

The dose effect is confirmed in all the studied parameters. The antagonist activity at the glycoprotein IIb IIIa site for the compounds of the invention also applies to other agonists, such as serotonin, arachidonic acid, epinephrine, adrenaline, ristocetine and thrombin.

**Example 22 : Human in vivo test**

Two volunteers (with a weight of about 70-75 kg), considered as heavy smokers (smoking more than 10 cigarettes / day) have orally taken capsules (gastro soluble) containing 5g anhydrous glycine betaine/ day during 7 days.

Before administration of the betaine, the aggregations induced by ADP, by collagen, by epinephrine, by adrenaline, by thrombin, by ristocetine and by arachidonic acid were determined. After one week treatment, the same platelet aggregations were measured. It appears from said tests that all the induced platelet aggregations were reduced for all said endogenous agonists of at least 30%.

Better results are expected when using oral dosage form with controlled release, such as gastro insoluble, but entero soluble form.

**Example 23 : anti-haemorrhagic activity**

Rats have been used in this test. Some rats received an active agent with haemorrhagic side effect, while other rats received said active agent together with a dose of betaine.

The following products were administered to rats for determining whether glycine betaine has an anti-haemorrhagic effect:

100 mg aspirin per kg life body

100 mg aspirin + 50 mg glycine betaine per kg life body

2 mg heparin

2 mg heparin + 50 mg glycine betaine

2 mg heparin + 10 mg glycine betaine

5 2 mg heparin + 2 mg glycine betaine

When inducing a haemorrhage, it was observed that the bleeding time was reduced when glycine betaine was administered. It means therefore that glycine betaine has anti-haemorrhagic properties.

10 In view of the above specification, the invention relates thus also to :

- the use of a compound of formula  $(\text{CH}_3)_3\text{N}^+ - (\text{CH}_2)_n - \text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof for the preparation of a pharmaceutical composition for the treatment or the prevention of troubles bound to one or more glycoproteins, especially to receptor of one or more glycoproteins, preferably to receptor of glycoprotein IIb IIIa,
- 15 - the use of a compound of formula  $(\text{CH}_3)_3\text{N}^+ - (\text{CH}_2)_n - \text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof for the preparation of a pharmaceutical composition for the treatment or the prevention of troubles bound to one or more glycoproteins, especially to receptor of one or more glycoproteins, preferably to receptor of glycoprotein IIb IIIa for inhibiting the platelet aggregation,
- 20 - the use of a compound of formula  $(\text{CH}_3)_3\text{N}^+ - (\text{CH}_2)_n - \text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof for the preparation of a pharmaceutical composition for the treatment or the prevention of troubles bound to one or more glycoproteins, especially to receptor of one or more glycoproteins, preferably to receptor of glycoprotein IIb IIIa for avoiding the adhesion of cells there between
- 25
- 30

- Pharmaceutical composition comprising insulin and at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof
- 5 - Pharmaceutical composition comprising an anticancerous agent and at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof
- Pharmaceutical composition comprising an antibiotic and at least a  
10 compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more  
15 pharmaceutically acceptable salts thereof, as glycoproteic antagonist agent, in particular as antagonist of the glycoprotein IIb IIIa, for the preparation of a pharmaceutical composition
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or  
20 more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to cancer, in particular to the metastasis of cancerous cells
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer  
25 from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to blood circulation, in particular to the blood microcirculation
- 30 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or

more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to nicotine addiction

- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer  
5 from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to obesity

- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer  
10 from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutically active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to hemophilia

- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer  
15 from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to chemotherapy

- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer  
20 from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of diabetic troubles

- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer  
25 from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to aging

- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer  
30 from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent

for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to oestrogen oral contraception

- 5    - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutically active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to extracorporeal blood circulation, in particular to troubles bound to dialysis and to hemodialysis
- 10   - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to inflammation, in  
15   particular internal inflammation troubles
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the  
20   prevention or the stabilization of troubles bound to bites, in particular to bites of venomous animals,
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent  
25   for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to post traumatic shock or post surgical shock,
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer  
30   more pharmaceutically acceptable salts thereof, as therapeutic active agent

for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to septic shocks,

5 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to hemorrhage, in particular to internal hemorrhage, such as a cerebral hemorrhage,

10 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to embolism, in particular to cerebral embolism and/or pulmonary embolism

15 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to an infract

20 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutically active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to aneurysm

25 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to phlebitis

30 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or



more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to angina pectoris

- 5       - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of thromboses troubles, in particular troubles bound to reocclusion of the vascular system and/or to thrombolysis and/or to angioplasty

- 10       - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to the use of hemoplastic or hemostatic glues, in particular fibrinogen glue, fibrin glue, collagen glue, thrombin glue

- 15       - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to pregnancy

- 20       - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of thromboses troubles, in particular coronary thrombosis and/or venous thrombosis

- 25       - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent
- 30

for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to trip or travel, in particular travel in airplane, buses, trains, racket, space shuttle, preferably travel at speed of more than 200 km/h

- 5 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to travel, in particular to
- 10 travel in pressurized environment
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent for the preparation of a pharmaceutical composition for the treatment or the
- 15 prevention or the stabilization of bacterial troubles and/or infectious troubles and/or troubles due to virus and/or troubles due to fungus
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent
- 20 for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of asthmatic troubles
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent
- 25 for the preparation of a pharmaceutical composition for the treatment or the prevention or the stabilization of troubles bound to osteoporosis
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as therapeutic active agent
- 30 for the preparation of a pharmaceutical composition for the treatment or the

prevention or the stabilization of troubles bound to graft of skin and/or tissue and/or bone and/or cells

- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as antagonist agent for serotonin and/or arachidonic acid and/or epinephrine and/or adrenaline and/or thrombin and/or ristocetine for the preparation of a pharmaceutical composition
- Uses as disclosed here before for the preparation of a pharmaceutical form, possibly as a kit, containing an active agent different from compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, for the administration (simultaneous or successive, with the same or different administration path) of said other therapeutic active agent and of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof
- Sweetening composition containing at least a sweetener and at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof
- Sweetening composition containing at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof
- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as agent for improving the sweetening property of a sweetener, in particular of a synthetic sweetener
- Process for detecting and/or localising and/or separating thrombi in vitro and/or in vivo, possibly in an extra corporal loop or circuit, in which blood is

mixed or added with at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

5 - Preserving process for cells and/or platelets in a medium, in particular in a blood medium or a fraction thereof, in which said medium is added or mixed with compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

10 - Process for the isolation and/or individualisation of cells and/or platelets in a medium, in particular in a blood medium or a fraction thereof, in which said medium is added or mixed with at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

15 - Platelet rich plasma (blood plasma) or platelet poor plasma, said plasma containing at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

20 - Process for the culture of cells in a medium or on a support or in a bioreactor, in particular in a blood medium or a fraction thereof, in which said medium is added or mixed with at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

25 - Process for the preparation of fibrin and/or collagen by reaction of fibrinogen or collagen in presence of at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

30 - glue (such as a hemostatic glue) containing at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or

a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

- Device with a surface in contact with fibrin and/or fibrinogen and/or collagen, said surface being made of and being treated with a composition  
5 containing at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

- Composition containing at least fibrinogen and at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal  
10 to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

- Composition containing at least collagen and at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal  
15 to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

- Process for the treatment of blood or a fraction thereof by osmosis and/or reverse osmosis, in which , before and/or during and/or after the osmosis or reverse osmosis, said blood is added or mixed with at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal  
20 to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

- Process for the treatment of blood or a fraction thereof by centrifugation, in which , before and/or during and/or after the centrifugation, said blood is added or mixed with at least a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$   
25 with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof

- Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof for the preparation of a  
30 pharmaceutical or cosmetic composition for the treatment or prevention or stabilization of hair troubles, in particular troubles due to hair losses

- Biological material or synthetic material for implant purposes, especially for bone implant, said material being treated with a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, and/or a composition containing such a compound
- 5 - Process of treatment of a patient suffering of a trouble cited hereabove in this specification, in which an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof is administered to said patient, so as to treat and/or stabilize said trouble
- 10 - Process for preventing a patient to suffer a trouble cited hereabove in this specification, in which an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof is administered to said patient, so as to prevent said trouble,
- 15 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as antiagglutinant agent, for the preparation of a pharmaceutical composition
- 20 - Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably equal to 1, or a mixture of such compounds or one or more pharmaceutically acceptable salts thereof, as blood fluidifying agent, for the preparation of a pharmaceutical composition.

**EXAMPLE 24**

Tablets having the following formulation were prepared:

5	
	<hr/>
	mg/tablet
	<hr/>
	Betaine, preferably glycine betaine Anhydrous 100
	Lactose Ph. Eur. 68.0
10	Ethylcellulose (Surelease .RTM. 25% solids)
	15
	Purified Water Ph. Eur.
	13.3*
	Cetostearyl Alcohol Ph. Eur.
15	42.00
	(Dehydag wax 0)
	Magnesium Stearate Ph. Eur.
	2.00
	Purified Talc Ph. Eur. 3.00
20	230.00
	<hr/>

\*Removed during processing.

Betaine, preferably glycine betaine anhydrous (100 mg) and lactose (68 mg)  
 25 were granulated, transferred to a fluid bed granulator and sprayed with  
 ethylcellulose (15 mg) and water. The granules were then dried at 60.degree.  
 C. and passed through a 1 mm screen.

To the warmed betaine, preferably glycine betaine containing granules was  
 30 added molten cetostearyl alcohol (42 mg) and the whole was mixed  
 thoroughly. The granules were allowed to cool and sieved through a 1.6 mm

screen. Purified talc and magnesium stearate were added and mixed with the granules. The granules were then compressed into tablets.

The tablets were coated with a film coat having the formulation given below.

5	
	<hr/>
	mg/tablet
	<hr/>
	Hydropropylmethylcellulose
	0.770
10	Ph. Eur. 15 cps (Methocel E15)
	Hydroxypropylmethylcellulose
	3.87
	(Ph. Eur. 5 cps (Methocel E5)
	Opaspray M-1-7111B (33% solids)
15	2.57
	Polyethylene glycol 400 USNF
	0.520
	Purified Talc Ph. Eur.
	0.270
20	Purified Water Ph. Eur.
	55.52*
	<hr/>

\*Remove during processing.

25 **EXAMPLE 25**

Tablets having the following formulation were prepared:

	<hr/>
	mg/tablet
30	<hr/>
	Betaine, preferably glycine betaine anhydrous



	100.0
	Lactose Ph. Eur. 58.0
	Ethylcellulose USNF 15.0
	(Ethocel 45 CP)
5	Cetostearyl alcohol Ph. Eur.
	52.0
	(Dehydag wax O)
	Magnesium stearate Ph. Eur.
	2.00
10	Purified talc Ph. Eur.
	3.00

---

- 15 A mixture of betaine, preferably glycine betaine anhydrous (100 mg), lactose (58 mg) and ethylcellulose (15 mg) was granulated while adding molten cetostearyl alcohol (52 mg) and the whole was mixed thoroughly. The granules were allowed to cool and sieved through a 1.6 mm screen. Purified talc and magnesium stearate were added and mixed with the granules. The
- 20 granules were then compressed into tablets which were coated with a film coat having the formulation given in Example 24.

#### **EXAMPLE 26**

- 25 Film coated tablets were produced following the procedure described in Example 25 and having the following formulation:

---

	mg/tablet
30	Betaine, preferably glycine betaine anhydrous
	100.00

73

	Lactose Ph. Eur.	70.50
	Hydroxyethylcellulose Ph. Eur.	
		12.50
	Cetostearyl alcohol Ph. Eur.	
5		42.00
	Magnesium stearate Ph. Eur.	
		2.00
	Purified talc Ph. Eur.	
		3.00
10	<hr/>	

#### In vitro dissolution studies

- 15 In vitro dissolution studies were conducted on tablets prepared as described above. Results are given in Table 1.

TABLE 1

20 WT % BETAINES, PREFERABLY GLYCINE BETAINES RELEASED

Time (h) Example 24 Example 25 Example 26

	1	39	35	43
	2	52	47	60
25	4	67	62	84
	8	82	78	97
	12	90	86	--

\*Measured on tablet core

30

**EXAMPLES 27 and 28**

Particles having the formulations given in Table II below, were prepared by the steps of:

5

i. Placing the ingredients (a) and (c) (total batch weight 0.7 kg) in the bowl of a 10 liter capacity Collette Gral Mixer (or equivalent) equipped with variable speed mixing and granulating blades;

10

ii. Mixing the ingredients at about 150-1000 rpm whilst applying heat until the contents of the bowl are agglomerated.

iii. Classifying the agglomerated material by passage through a Comil and/or Jackson Crockatt to obtain controlled release seeds.

15

iv. Warming and mixing the classified material in the bowl of a 10 liter Collette Gral, until uniform multiparticulates of the desired pre-determined size range are formed in yield of greater than 80%. This takes approximately 5 minutes.

20

v. Discharging the multiparticulates from the mixer and sieving them to separate out the multiparticulates collected between 0.5 and 2 mm aperture sieves.

TABLE II

25

Example	27	28
(a) Betaine, preferably glycine betaine Anhydrous (Wt %)	50	75
(b) Hydrogenated Vegetable Oil (Wt %)	50	25

30

**EXAMPLE 29**

Samples of the particles from Example 4 were blended with magnesium  
 5 stearate and purified talc using a Y-Cone or bin-blender. The blended mixture  
 was then compressed using either (1) 14.times.6 mm, (2) 16.times.7 mm or  
 (3) 18.6.times.7.5 mm capsule shaped tooling on a single punch F3 Manesty  
 tableting machine to give tablets giving 200, 300 and 400 mg of betaine,  
 preferably glycine betaine anhydrous. The ingredients per dosage unit  
 10 amounted to the following:

TABLE III

15	TABLET	MG/TABLET		
	INGREDIENT	29(1)	29(2)	29(3)
	Betaine, preferably glycine betaine Anhydrous	200	300	400
	Hydrogenated Vegetable Oil	200	300	400
	Sub Total	400	600	800
20	Purified Talc	12.63	18.95	25.26
	Magnesium Stearate	8.42	12.63	16.84

The tablets were assessed by the dissolution using Ph. Eur. Paddle Method  
 100 rpm, 0.1N HCl.

25

To assess the non-compressed particles the Ph Eur. Paddle was replaced by a  
 modified Ph Eur. Basket.

The results are shown in Table IV below;

30

TABLE IV

5	HOURS AFTER				
	START OF TEST	% BETAINE, PREFERABLY GLYCINE BETAINE			
		Anhydrous RELEASED			
		Particles	Tablet 29(1)	tablet 29(2)	Tablet 29(3)
10	1	54	16	15	15
	2	68	23	20	21
	3	76	28	25	25
	4	82	32	28	28
	6	89	40	35	35
	8	93	46	41	40
15	10	96	50	45	45
	12	98	55	49	49
	16	100	63	57	56
	20	NR	70	63	NR

20

These results confirm the effectiveness of the tableting in reducing the release rate.

25 **EXAMPLE 30**

Samples of the particles from Example 28 were then tabletted using a procedure similar to Example 26 and the ingredients per unit dosage amounted to:

TABLE V

5	TABLET	MG/TABLET		
	INGREDIENT	30(4)	30(5)	30(6)
	Betaine, preferably glycine betaine Anhydrous	200	300	400
	Hydrogenated Vegetable Oil			
10		66.7	100	133
	Sub Total	266.7	400	533
	Purified Talc	7.63	11.44	15.25
	Magnesium Stearate	5.16	7.63	10.17

15 The tablets and samples of non-compressed multiparticulates (each sample containing 400 mg of betaine, preferably glycine betaine anhydrous) were assessed by the dissolution method also described above. The results are shown in Table VI below;

20 TABLE VI

25	HOURS AFTER	Particles	Tablet 30(4)	Tablet 30(5)	Tablet 30(6)
	START OF TEST	% BETAINE, PREFERABLY GLYCINE BETAINE Anhydrous	RELEASED		
	1	77	43	40	42
	2	92	64	55	56
	3	98	75	65	66
	4	100	83	72	73
30	6	102	94	83	84
	8	102	100	91	91
	10	102	NR	96	97

These results show that by increasing the loading of the highly water soluble betaine, preferably glycine betaine anhydrous (75% w/w in this example compared with 50% w/w in Example 29) a significantly faster release rate of the active ingredient can be achieved.

5

**EXAMPLE 31**

Example 27 was repeated but with the following formulation:

10	Betaine, preferably glycine betaine Anhydrous
	200 mg/tablet
	Hydrogenated Vegetable Oil
	163.0 mg/tablet

15

The resulting multiparticulates were blended as described in Example 29 with the following;

	Purified Talc	11.5 mg/tablet
20	Magnesium Stearate	7.66 mg/tablet

The blend was then compressed as described in Example 29 but using 15 mm. times. 6.5 mm normal concave capsule shaped plain/plain punches.

The resulting tablets were then assessed by the dissolution method described above. The results are shown in Table V.

5	HOURS	% BETAINES, PREFERABLY GLYCINE
	AFTER START OF TEST	BETAINES Anhydrous RELEASED
	1	20
	2	27
	3	32
10	4	37
	6	44
	8	50
	10	55
	12	60
15	16	67
	20	73
	24	77

20 The examples provided above are not meant to be exclusive. Many other variation of the present invention would be obvious to those skilled in the art, and are contemplated to be within the scope of the appended claims.

25 The man skilled in the art can adjust the release rate of a patch so as to have an adapted betaine concentration in the blood, for a period of for example 6 hours, 12 hours, 24 hours, etc.

The patch structure can be as taught in US 4,911,916, US4,917,676, US 5,536,503 and US 5,486,362, the scope of which is incorporated by reference.

30 In said patch structure, a betaine of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably glycine betaine or a pharmaceutically



acceptable salt thereof, esters thereof, precursors thereof, and mixtures thereof is used as active agent instead of the proposed active agent. The drawings of said patents (especially figures 2 and 3 of US 5536503) are incorporated by reference for teaching the possible form and structure of the patch.

Transdermal patches have a variety of advantages including avoidance of the gastro-intestinal tract, sustained action which readily can be adjusted, self-administration and the ability to immediately discontinue dosage. The term transdermal patch is intended to include patches capable of being affixed to the skin of an individual and having a part or component capable of delivering an active agent (a betaine of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof, esters thereof, precursors thereof, mixtures thereof), in a controlled sustained release manner. Examples of types of patches useful in this invention include those having a diffusion layer matrix and/or multicompartamental type patches. These will be described below for glycine betaine as active agent. There are many transdermal patches known to those of ordinary skill in the art and well described in the prior art. One such patch useful involves a diffusion matrix layer that uses a reticulated macroporous polymeric foam as a framework for holding a viscoelastic glycine betaine-polymer mixture. The patch is for example a multi (4 or more)-layer, laminated composite that is adapted to be adhered to the skin. The outermost layer, backing layer, functions as the primary structural element of the device as well as serving as a protective covering to prevent the glycine betaine from being transmitted from the device via the outermost surface. Backing layer preferably is made of a sheet or film of a resilient elastomer of about 10-75 microns thick. Examples of such elastomers include polyether block amide copolymers, polyethylene methacrylate block copolymers, polyurethanes, silicon elastomers and the like.

The glycine betaine-containing matrix layer functions as a reservoir for glycine betaine (possibly an enhancer), and optionally a pressure sensitive adhesive. The framework of the matrix is a reticulated macroporous polymeric foam. Preferably the network is essentially completely open pores  
5 (90% or greater). The pore rating of the reticulated foam will normally be in the range of about 10-40 pores per linear centimeter and the density (unfilled) will typically be in the range of about 0.01 to 0.5 g/cm<sup>3</sup>. Suitable polymers from which such foam frameworks may be manufactured include polyurethanes and polyethylenes.

10 A pressure sensitive adhesive layer covers the exposed face of the matrix layer and a release liner covers the pressure sensitive adhesive. The pressure sensitive adhesive layer is a medical grade adhesive composition having a thickness normally between about 25 and 100 microns. An example of such an adhesive is polydimethylsiloxane (Dow Corning 355 medical grade  
15 adhesive).

The pores of the foam are wholly or partly filled with a viscoelastic hydrophobic betaine-permeable polymer (and an enhancer if present). The polymer acts as a carrier for the glycine betaine, while the enhancer acts to  
20 control the solubility of the glycine betaine in the polymer and/or absorption of the drug into the skin. The hydrophobic polymer renders the device water-resistant and prevents liquid water from being absorbed by the device, thereby increasing its functionality and wearability. Examples of such polymers are polysiloxanes (silicone polymers), hydrophobic polyacrylates,  
25 polyurethanes, plasticized ethylene-vinyl acetate copolymers and the like. An example of a useful enhancer includes Azone. TM.. Another example of a useful dermal permeation enhancer includes transcutol. The mixture including the glycine betaine optionally includes an anti-pruritic agent.

30 Devices of the foregoing nature are generally described in U.S. Pat. No. 4,911,916, entitled "Diffusion Matrix for Transdermal Drug Administration

and Transdermal Drug Delivery Devices Including Same", issued Mar. 27, 1990, the entire disclosure of which is incorporated herein by reference. Such patches may be configured to contain sufficient glycine betaine to release from about five milligrams to 5 grams of glycine betaine, such as from 100 to  
5 500 milligrams per day. Preferably such patches are configured to hold sufficient betaine to release from about five to about 500 milligrams per day for seven days, such that a single patch may be worn for one week.

The optimum dose range, i.e., the range of doses with which the drug exhibits  
10 maximum therapeutic effect (and minimum adverse side effects for the other drug or therapeutic agent of the combination, when the patch is used in such a combination) can be determined empirically. The patch or other delivery system is configured and formulated to contain sufficient glycine betaine to release a dose within the optimum dose range for the desired period of time.

15 Another patch useful is a 4-layer composite defining at least two separate compartments. One compartment contains glycine betaine, and the other compartment contains a delivery substance that when mixed with glycine betaine permits the delivery of the glycine betaine transdermally. The patch  
20 has a backing layer sealed to a rate controlling membrane in a manner to create two chambers, betaine containing chamber and a delivery substance containing chamber. An adhesive layer covers the rate controlling membrane and a release sheet covers the adhesive layer.

25 To form the device, a silanized polyester (or other suitable material treated with a releasing agent) approximately 75 microns thick, is used as a release sheet 34. The adhesive layer 32 is cast onto the release sheet, and may be for example polyisobutylene. The adhesive layer then is laminated to the rate controlling membrane 26, which may be about 100 microns thick. Ethylene-  
30 vinyl acetate may be employed for the control membrane.

Next, the materials which will become the contents of the betaine containing chamber and delivery substance chamber are placed in separate areas on the rate controlling membrane. The material for the betaine containing chamber may be betaine free base and the material for the delivery substance  
5 containing chamber may be an alcoholic or aqueous/alcoholic solution or water.

Finally, a suitable backing having a heat sealable coating on one surface is placed over the two areas which are to become the two chambers, and the  
10 device is heat sealed around the perimeter and between the two areas to form the two chambers. The heat seal between the two chambers should be less secure than the heat seal about the perimeter, so that the seal between the chambers will selectively burst under pressure applied by the user. In this manner, pressure may be applied to either one of the chambers to burst the  
15 seal between the chambers, thereby mixing the solution and the betaine and dissolving the glycine betaine (anhydrous). The betaine then is in a form which is capable of passing through the rate controlling membrane for delivery to the skin of the user. As with the patch disclosed in the first embodiment, the chambers may include enhancers or retarder for affecting  
20 uptake of the betaine across the skin.

Preferred forms of the foregoing patch are shown in greater detail in U.S. Pat. No. 4,917,676, issued Apr. 17, 1990 and entitled "User-Activated Transdermal Therapeutic System", the entire disclosure of which is  
25 incorporated herein by reference. Such patches should contain sufficient lobeline to release from about five to about 500 milligrams of glycine betaine per day (from 2 to 10 mg/kg), and such patches are suitable to provide individual, daily patches.

**Example 32**

In said example parenteral (especially subcutaneous) solutions containing  
5 heparin and glycine betaine have been prepared.

For example, the solutions of heparin sodium sold by CHOAY® (25000 IU/ml, aqueous solution), sold by LEO® and sold by ROCHE® were mixed with glycine betaine as a powder or as an aqueous solution, so as to prepare injectable solutions containing 25000 IU, 5000 IU and 2500 IU heparin  
10 (corresponding to 5 ml injectable solutions containing 5 mg /ml heparin and 100 mg/ml glycine betaine, injectable solutions containing 1 mg/ml heparin and 20 mg/ml glycine betaine, and injectable solutions containing 0,5 mg/ml heparin and 10 mg/ml glycine betaine).

15 **Example 33**

In said example oral formulations containing aspirin ( acid acetylsalicylic) and glycine betaine have been prepared.

A) acid acetylsalicylic 500 mg + 500 mg betaine + excipient

B) acid acetylsalicylic 300 mg + 200 mg betaine + excipient

20 C) acid acetylsalicylic 300 mg + 400 mg betaine + excipient

A, B and C being possibly coated with an enterosoluble or controlled release layer, such as tablet or pellet. Or A, B and C being possibly placed in a capsule with an enterosoluble or controlled release layer.

D) a syrup containing acid acetylsalicylic + betaine.

25

**Example 34**

**Induced haemorrhagic time IHT**

( E. Dejana. Bleeding time in rats . Thrombosis. Rech. 1982 )

Male Wistar rats were used for these tests. They weighed between 240 and  
30 260 grams. The effect of various solutions ( NaCl 0,9%, betaine anhydrous 10 mg/kg, heparin sodium CHOAY® 5 mg/ kg, combination betaine

anhydrous 10 mg/kg + heparin CHOAY® 5 mg/ kg ) on the (IHT) or induced haemorrhagic time was tested.

The tail of anaesthetised rat, is dipped for 5 minutes in a water bath at 37°C, so as to provoke a dilatation of the peripheral vessels, which are removed and cut at the end ( 6 to 10 mm from the end of the tail ), the chronometer being started. The IHT is defined as being the time period comprised between the cutting of end tail and the end of the haemorrhage or bleeding. The end of haemorrhage is defined as the time where the last drop of blood is removed from the tail and where no other drop is seen during 180 seconds. The substances were subcutaneously administrated 60 minutes prior to the tail cut. In the combination test betaine 10 mg/ kg and heparin 5 mg/ kg were simultaneously administrated.

The results of said test are given in seconds in the following table.

	Reference NaCl 0,9%	Betaine 10 mg/ kg	Heparin 5 mg/ kg	Combination Betaine 10 mg + Heparin 5 mg
Rat N° 1	110	162	767	218
Rat N° 2	110	173	680	176
Rat N° 3	156	194	734	**
Rat N° 4	140	203	702	231
Rat N° 5	165	159	**	229
Rat N° 6	180	142	663	155
Rat N° 7	106	123	735	278
Rat N° 8	156	197	567	192
Rat N° 9	97	166	**	202
Rat N° 10	*	180	679	257
	n = 9	n = 10	n = 8	n = 9
<b>mean</b>	<b>135,6</b>	<b>169,9</b>	<b>690,9</b>	<b>215,3</b>
<b>Standard deviation</b>	<b>30,3</b>	<b>25,2</b>	<b>61,1</b>	<b>38,7</b>

\* rat dead after the anesthesia

**\*\* not measured ( no haemorrhage 3 minutes after cutting the end tail )**

This test shows clearly that the combined use of heparin with betaine prevent and reduces drastically the haemorrhagic side effect due to heparin. The simultaneous administration of betaine with heparin reduced in a statistically significant manner the volume of blood loss comparatively to the group where heparin was administrated alone. It was noted a reduction by more than 3 folds of blood loss in the combination group comparatively to the group where heparin was administrated alone.

The combinations as described in examples may be useful in human clinic, particularly to natural haemorrhagic events linked to thrombosis and cardiovascular diseases or linked to drugs administration side effects following various diseases.

**WHAT I CLAIM IS :**

1. A pharmaceutical combination comprising a therapeutic effective amount of a therapeutically active agent with at least one haemorrhagic side effect, and a therapeutic effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof, esters thereof, precursors thereof, and mixtures thereof for preventing or reducing said haemorrhagic side effect and/or for potentialising the therapeutic effect of said active agent.
- 2 The pharmaceutical combination of claim 1, in which the therapeutic active agent has at least possible haemorrhagic side effects, and in which the combination comprises a therapeutic effective amount of glycine betaine for preventing substantially completely said haemorrhagic side effect.
3. The pharmaceutical combination of claim 1, in which glycine betaine is in a form suitable for subcutaneous injection or in a form suitable for the preparation of a form for subcutaneous injection.
4. The pharmaceutical combination of claim 1, in which the therapeutic agent with at least possible side effect is selected from the group consisting of anti vitamin K, anti aggregants, anticoagulants, anti thrombin, fibrinolytics and mixtures thereof.
5. The pharmaceutical combination of claim 1, in which the therapeutic agent with at least possible haemorrhagic side effect is selected from the group consisting of:  
anti aggregants such as



abciximab, acetylsalicylate basic aluminium, acetylsalicylate carbonate sodium, acetylsalicylate lysine, acetylsalicylic acid, aloxiprine, anagrelide chlorhydrate, bencyclane furamate, carbasalate calcium, clopidogrel sulfate, epoprostenol sodium, epifibatide, hydroxychloroquine sulfate, iloprost, 5 nicergoline, nifedipine, pyricarbonate, sulfinpyrazone, ticlopidine chlorhydrate, tirofiban chlorhydrate, verapamil chlorhydrate, and compounds structurally similar to one of the preceding anti aggregant compounds, and mixtures thereof,

10 and/ or anticoagulants such as

acenocoumarol, anisindione, biscoumacetate ethyl, bromindione, coumatetral, dalteparine sodium, sirudine, xtran sulfate, enoxaparine sodium, fluindione, heparinate magnesium, heparin calcium, heparine sodium, lepirudine 15 nadroparine calcium, oxazindione, pentosan polysulfate, phenindione, phenprocoumon, reviparine sodium, tinzaparine sodium, ticlofenac, warfarine sodium, glycosaminoglycans, heparins, unfractionated heparin, standard heparin, low molecular heparins, heparinoids, heparin-like molecules and compounds structurally similar to one of the preceding anti 20 coagulant compounds, and mixtures thereof,

and/ or fibrinolytics such as

alteplase, anistreplase, atorvastatin calcium, bromelains, ciprofibrate, 25 defibrotide, fluvastatin sodium, glicazide, lovastatin, lys-plasminogen, phenformin, pravastatin sodium, reteplase, simvastatin, streptokinase, urokinase, and compounds structurally similar to one of the preceding fibrinolytic compounds., and mixtures thereof ,

30 and/or thrombin inhibitor such as

argatroban, novastan, and mixtures thereof,

and/or anti vitamin K,  
and mixtures thereof.

- 5 6. The pharmaceutical combination of claim 1, in which the therapeutic active agent which is an antithrombotic agent with possible side effect and the glycine betaine are in a form suitable for simultaneous administration or successive administration or for administration according to different paths.
- 10 7. Use of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof, esters thereof, precursors thereof, and mixtures thereof, as active antidote agent for the preparation of an antidote composition.
- 15 8. Process of treatment of a patient in need for treating or preventing a trouble by administering to said patient an effective amount of a therapeutic active agent with at least possible one side haemorrhagic side effect, in which an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof, esters thereof, precursors thereof, and mixtures thereof for preventing or reducing said side effect and/or for potentializing the therapeutic effect of said therapeutically active agent.
- 20 9. Process of treatment of a patient in need for treating or for preventing thrombosis troubles for a patient, by administering to said patient a therapeutic effective amount of an anti thrombotic active agent with at least one possible haemorrhagic side effect, in which before and/or during and/or after said administration, a therapeutic effective amount of glycine betaine is administered to said patient for preventing or reducing said haemorrhagic side effect.
- 30

10. The process of claim 9, in which the glycine betaine is subcutaneously injected.

11. A controlled release pharmaceutical system suitable for delivering in a controlled manner to the bloodstream of a mammalian a betaine or an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, preferably glycine betaine or a pharmaceutically acceptable salt thereof, esters thereof, precursors thereof, and mixtures thereof.

10

12. The system of the preceding claims, which is an oral controlled release preparation or device.

13. The system of claim 11, which is a transdermal controlled release preparation or device, especially a patch.

14. The system of any one of the claims 11 to 13 for releasing as active ingredient glycine betaine.

15. A controlled release pharmaceutical system for releasing an effective therapeutically amount of at least a compound selected from the group consisting of betaines or an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, for treating or preventing blood flow disturbances.

16. A controlled release pharmaceutical system for releasing an effective therapeutic amount of at least a compound selected from the group consisting of betaines, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, for treating or preventing thrombosis and/or thromboembolic disorders.

30

17. The system of any one of the preceding claims 11 to 16, in which the system controls at least for 10 minutes, advantageously at least for 15 minutes, preferably at least for 30 minutes, the release of at least a compound selected from the group consisting of betaines or an effective amount of a  
5 compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof.

18. The system of any one of the preceding claims 11 to 16, in which the system controls at least for 60 minutes, advantageously at least for 90  
10 minutes, preferably at least for 120 minutes, the release of at least a compound selected from the group consisting of betaines or an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof.

19. The system of any one of the claims 11 to 16, in which the system controls at least for 180 minutes, advantageously at least for 240 minutes, preferably at least for 360 minutes, most preferably at least for 1440 minutes, the release of at least a compound selected from the group consisting of  
20 betaines or an effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, precursors thereof, and mixtures thereof.

20. The system and/or the device of any one of the claims 11 to 19, in which the system or device comprises one or more electronic device or chips controlling one or more releasing system or device.

21. A method for treating or preventing a blood flow disturbance and/or thrombosis and/or thromboembolic disorders, in which a therapeutic effective  
30 amount of a betaine or a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with n

an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof is administered in a controlled manner to the blood stream of a mammalian.

22. The method of claim 21, in which the administration is a transdermal  
5 administration.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number  
**WO 02/062322 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/205**,  
A61P 9/00

(21) International Application Number: PCT/BE02/00013

(22) International Filing Date: 4 February 2002 (04.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2001/0085 5 February 2001 (05.02.2001) BE  
09/945,391 31 August 2001 (31.08.2001) US  
PCT/BE01/00222  
21 December 2001 (21.12.2001) BE

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

Published:  
— with international search report

(71) Applicant and  
(72) Inventor: **MESSADEK, Jallal** [BE/BE]; Place des  
Béguinages 2, B-4000 Liège (BE).

(88) Date of publication of the international search report:  
28 November 2002

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/062322 A3

(54) Title: GLYCINE BETAINE AND ITS USE AS ANTI-HEMORRHAGIC AGENT

(57) Abstract: A pharmaceutical combination comprising a therapeutic effective amount of a therapeutically active agent with at least one haemorrhagic side effect, and a therapeutic effective amount of a compound of formula  $(\text{CH}_3)_3\text{N}^+(\text{CH}_2)_n\text{COO}^-$  with  $n$  an integer from 1 to 5 for preventing or reducing said haemorrhagic side effect.

## INTERNATIONAL SEARCH REPORT

Inventor's Application No  
PCT/BE 02/00013

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K31/205 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, PHARMAPROJECTS, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	BE 1 012 712 A (MESSADEK JALLAL) 6 February 2001 (2001-02-06)	7
P,Y	page 2, line 43 -page 3, line 12 claims 1,2	1-6
X	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 08, 6 October 2000 (2000-10-06) & JP 2000 143486 A (LION CORP), 23 May 2000 (2000-05-23) abstract	1,2,4-6, 11,13-16
X	BE 1 012 546 A (MESSADEK JALLAL) 5 December 2000 (2000-12-05)	7,11, 14-16
Y	page 1, line 15 -page 2, line 5 page 3, line 1 - line 42 examples 1-10 claim 16	1-6
	-/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

14 June 2002

Date of mailing of the international search report

20/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Glabobbe, S

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/BE 02/00013

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 51596 A (MESSADEK JALLAL) 8 September 2000 (2000-09-08)	7
Y	page 2, line 20 - line 44 page 3, line 36 - line 50 examples 1-7	1-6
X	WO 97 06795 A (KALVINSH IVARS ;VEVERIS MARIS (LV)) 27 February 1997 (1997-02-27) abstract claims 1-10	11-13, 15,16
X	US 5 876 780 A (KOIVISTOINEN MIKA ET AL) 2 March 1999 (1999-03-02) claim 1	11,12, 14-16
X	VINSON, M.C., ET AL.,: "New Drug Approvals of 1996. Part 3" DRUG TOPICS, vol. 141, 1997, pages 7272-81, XP001080754	11,12, 14-16
X	DATABASE PHARMPAT 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1995 "naproxen betainate" Database accession no. 19011 XP002202249 abstract	1,2,4-7
A	EP 0 349 902 A (CHIESI FARMA SPA) 10 January 1990 (1990-01-10) page 2, line 17 - line 18	1,2,4-7



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/BE 02/00013

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8-10, 21, 22  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/BE 02/00013

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
BE 1012712 A	06-02-2001	BE 1012712 A6	06-02-2001
JP 2000143486 A	23-05-2000	NONE	
BE 1012546 A	05-12-2000	BE 1012546 A6	05-12-2000
WO 0051596 A	08-09-2000	BE 1012495 A3	07-11-2000
		AU 2897900 A	21-09-2000
		WO 0051596 A1	08-09-2000
		BR 0008631 A	13-02-2002
		CN 1342071 T	27-03-2002
		EP 1156796 A1	28-11-2001
		NZ 513905 A	28-09-2001
		US 2002065320 A1	30-05-2002
WO 9706795 A	27-02-1997	LV 11727 A	20-04-1997
		LV 11727 B	20-08-1997
		WO 9706795 A1	27-02-1997
US 5876780 A	02-03-1999	AU 682354 B2	02-10-1997
		AU 6570594 A	21-11-1994
		BR 9406511 A	09-01-1996
		CN 1141581 A	29-01-1997
		EP 0695127 A1	07-02-1996
		WO 9424886 A1	10-11-1994
		JP 8509372 T	08-10-1996
		US 5834473 A	10-11-1998
		US 5773052 A	30-06-1998
EP 0349902 A	10-01-1990	IT 1226386 B	15-01-1991
		DK 336289 A	09-01-1990
		EP 0349902 A2	10-01-1990
		FI 893293 A	09-01-1990
		KR 146352 B1	17-08-1998
		PT 91079 A ,B	08-02-1990